Downtime Plans Treatment & Therapy Plans
Loading Documents
- CAPEIRI_EVERY_21_DAYS
- CAPEIRI_BEVACIZUMAB_EVERY_21_DAYS
- CAPEOX_BEVACIZUMAB_EVERY_14_DAYS
- CAPEOX_CETUXIMAB_EVERY_14_DAYS
- CAPEOX_WEEKLY_CETUXIMAB_EVERY_21_DAYS
- CARBOPLATIN_AUC_5_WEEKLY_PACLITAXEL_BREAST_EVERY_21_DAYS
- CARBOPLATIN_DOCETAXEL_TRASTUZUMAB_PERTUZUMAB_EVERY_21_DAYS
- CARBOPLATIN_DOCETAXEL_TRASTUZUMAB_TCH_EVERY_21_DAYS
- CISPLATIN_GEMCITABINE_TORIPALIMAB_EVERY_21_DAYS
- CLL_IP_BENDAMUSTINE_100_RITUXIMAB_375_START_ON_DAY_1
- DOCETAXEL_DOXORUBICIN_CYCLOPHOSPHAMIDE_TAC_EVERY_21_DAYS
- DOCETAXEL_OXALIPLATIN_5FU_TFOX_EVERY_21_DAYS
- DOSTARLIMAB_1000_MG_MAINTENANCE_EVERY_42_DAYS
- DOSTARLIMAB_MONOTHERAPY_EVERY_21_DAYS_X_4_THEN_EVERY_42_DAYS
- ETOPOSIDE_D1_D5_CISPLATIN_D1_D5_TESTICULAR_CANCER_EVERY_21_DAYS
- GEMCITABINE_OXALIPLATIN_RITUXIMAB_EVERY_14_DAYS
- GEMCITABINE_D1D8_EVERY_21_DAYS
- IP_OP_RSH_PRO00036343_IMCGP100_203_ARM_A_TEBENTAFUSP
- IP_OP_RSH_PRO00036343_IMCGP100_203_ARM_B
- IP_OP_VAC_IE_EVERY_14_DAYS_INTERVAL_COMPRESSED
- IP_OP_VAC_IE_EVERY_21_DAYS
- IP_5FU_CONCURRENT_WITH_RADIATION
- IP_5FU_LEUCOVORIN_EVERY_14_DAYS
- IP_5FU_MITOMYCIN_CONCURRENT_WITH_RADIATION
- IP_ABVD
- IP_AC
- IP_AC_DOSE_DENSE
- IP_AIM
- IP_ALEMTUZUMAB
- IP_APL_INDUCTION_LOW_INTERMEDIATE
- IP_APLASTIC_ANEMIA_ATG_CSA
- IP_APML4_FIRST_CONSOLIDATION
- IP_APML4_INDUCTION
- IP_AUGMENTED_CVAD_PEGASPARGASE_C_VAD_DRUGS_PART_A_ARA_C_MTX_VINC_DRUGS_PART_B
- IP_AVD_BRENTUXIMAB
- IP_AYA_REMISSION_INDUCTION_CALGB_10403
- IP_AZACITIDINE_5_DAYS
- IP_AZACITIDINE_7_DAYS
- IP_BENDAMUSTINE_BORTEZOMIB_PREDNISONE
- IP_BEP
- IP_BEVACIZUMAB_10MG_KG_EVERY_14_DAYS
- IP_BLINATUMOMAB
- IP_BORTEZOMIB_EVERY_14_DAYS
- IP_BORTEZOMIB_DEXAMETHASONE_EVERY_21_DAYS
- IP_BORTEZOMIB_DEXAMETHASONE_EVERY_7_DAYS
- IP_BORTEZOMIB_DEXAMETHASONE_CYCLOPHOSHAMIDE
- IP_BRENTUXIMAB_VEDOTIN
- IP_CAGT_ALLOGENEIC_SCT_HAPLO_MEL_FLU_TBI_WITH_POST_TRANSPLANT_CYCLOPHOSPHAMIDE
- IP_CAGT_ALLOGENEIC_SCT_BU_CY_WITH_TACROLIMUS_and_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_BU_FLU_WITH_TACROLIMUS_and_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_CAMGRAFT
- IP_CAGT_ALLOGENEIC_SCT_CY_TBI
- IP_CAGT_ALLOGENEIC_SCT_CY_TBI_CAM
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_WITH_TACROLIMUS_and_MINI_METHOTREXATE_GVHD_PROPHYLAXIS
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_CAM
- IP_CAGT_ALLOGENEIC_SCT_FLU_MEL_PTCY
- IP_CAGT_ALLOGENEIC_SCT_FLU_TBI_PTCY
- IP_CAGT_ALLOGENEIC_SCT_FLU_CY_TBI_PTCY
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_CY_CAM
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_FLU_CAM
- IP_CAGT_ALLOGENEIC_SCT_IV_BU_FLU_PTCY
- IP_CAGT_ALLOGENEIC_SCT_IV_CLO_BU_CAM
- IP_CAGT_ALLOGENEIC_SCT_SAAHAPLO_ATG_RABBIT_CY_FLU_TBI_PTCY
- IP_CAGT_ALLOGENEIC_SCT_SAAMUD
- IP_CAGT_AUTOLOGOUS_MOBILIZATION_CYTARABINE
- IP_CAGT_AUTOLOGOUS_MOBILIZATION_HIGH_DOSE_CYCLOPHOSPHAMIDE
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_ETOPOSIDE_CARBOPLATIN_EINHORN_PROTOCOL
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_ETOPOSIDE_CARBOPLATIN_TICE_PROTOCOL
- IP_CAGT_AUTOLOGOUS_SCT_HIGH_DOSE_MELPHALAN
- IP_CAGT_AUTOLOGOUS_SCT_IV_BEAM
- IP_CAGT_AUTOLOGOUS_SCT_IV_BEAM_R
- IP_CAGT_AUTOLOGOUS_SCT_IV_CARMUSTINE_THIOTEPA_MATRIX
- IP_CAGT_PACLITAXEL_IFOSFAMIDE_TI_MOBILIZATION_FOR_GERM_CELL_TUMOR
- IP_CAGT_R_IE
- IP_CARBOPLATIN_AUC_6_DOCETAXEL_75_MG_M2
- IP_CARBOPLATIN_AUC_2_GEMCITABINE_EVERY_21_DAYS
- IP_CARBOPLATIN_AUC_5_GEMCITABINE_1000_MG_M2
- IP_CARBOPLATIN_AUC_5_LIPOSOMAL_DOXORUBICIN_30
- IP_CARBOPLATIN_AUC_6_PACLITAXEL_175_GYNECOLOGIC
- IP_CARBOPLATIN_ETOPOSIDE_EVERY_21_DAYS
- IP_CARBOPLATIN_GEMCITABINE
- IP_CARBOPLATIN_NAB_PACLITAXEL
- IP_CARBOPLATIN_PACLITAXEL_DOSE_DENSE
- IP_CARBOPLATIN_PACLITAXEL_LUNG
- IP_CARBOPLATIN_PACLITAXEL_BEVACIZUMAB
- IP_CARBOPLATIN_PACLITAXEL_BEVACIZUMAB_DOSE_DENSE
- IP_CARBOPLATIN_PACLITAXEL_W_CONCURRENT_THORACIC_RT
- IP_CARBOPLATIN_PEMETREXED
- IP_CARBOPLATIN_PEMETREXED_BEVACIZUMAB
- IP_CARBOPLATIN_DESENSITIZATION
- IP_CARFILZOMIB_INITIAL_CYCLE
- IP_CEOP
- IP_CHOP
- IP_CIA
- IP_CISPLATIN_DOCETAXEL_EVERY_21_DAYS
- IP_CISPLATIN_DOCETAXEL_5FU
- IP_CISPLATIN_DOXORUBICIN
- IP_CISPLATIN_ETOPOSIDE_EVERY_21_DAYS
- IP_CISPLATIN_ETOPOSIDE_W_CONCURRENT_THORACIC_RT_EVERY_21_DAYS
- IP_CISPLATIN_GEMCITABINE_EVERY_21_DAYS
- IP_CISPLATIN_IRINOTECAN_EVERY_21_DAYS_D1_D8
- IP_CISPLATIN_PACLITAXEL
- IP_CISPLATIN_PACLITAXEL_INTRAPERITONEAL
- IP_CISPLATIN_PACLITAXEL_BEVACIZUMAB
- IP_CISPLATIN_PEMETREXED
- IP_CISPLATIN_60_ETOPOSIDE_100_EVERY_21_DAYS
- IP_CISPLATIN_W_CONCURRENT_RT_EVERY_7_DAYS
- IP_CLADRIBINE_0.09_7_DAYS
- IP_CLADRIBINE_0.14_DAILY
- IP_CLAG
- IP_CLIA
- IP_CLOFARABINE_CYTARABINE
- IP_CODOX_A
- IP_CYBORDEX
- IP_CYCLOPHOSPHAMIDE_FLUDARABINE_LIFILEUCEL_HIGH_DOSE_IL_2
- IP_CYCLOPHOSPHAMIDE_VINCRISTINE_MERCAPTOPURINE_CYTARABINE_PEGASPARGASE
- IP_CYTARABINE_DAUNORUBICIN_GEMTUZUMAB_7_3
- IP_CYTARABINE_IDARUBICIN_7_3
- IP_CYTARABINE_100_DAUNORUBICIN_60_7_3
- IP_DARATUMUMAB
- IP_DEANGELIS_METHOTREXATE_VINCRISTINE_LEUCOVORIN_PROCARBAZINE_CYCLES_1_3_5
- IP_DEANGELIS_WITH_RITUXIMAB_METHOTREXATE_VINCRISTINE_LEUCOVORIN_CYCLES_2_AND_4
- IP_DEANGELIS_WITH_RITUXIMAB_METHOTREXATE_VINCRISTINE_LEUCOVORIN_PROCARBAZINE_CYCLES_1_3_5
- IP_DECITABINE_28_DAYS
- IP_DHAP
- IP_DOCETAXEL
- IP_DOCETAXEL_75_MG_M2_EVERY_21_DAYS
- IP_EP
- IP_EPOCH
- IP_ERIBULIN
- IP_ESHAP
- IP_FLAG_IDA
- IP_FLAG_IDA_CONSOLIDATION
- IP_FLAT_DOSE_CYTARABINE
- IP_FLUDARABINE_CYCLOPHOSPHAMIDE_RITUXIMAB
- IP_FOLFIRI_EVERY_14_DAYS
- IP_FOLFIRI_BEVACIZUMAB_EVERY_14_DAYS
- IP_FOLFIRINOX_EVERY_14_DAYS
- IP_FOLFOXIRI_EVERY_14_DAYS
- IP_FOLFOXIRI_BEVACIZUMAB_EVERY_14_DAYS
- IP_FOLFOXIRI_PANITUMUMAB_EVERY_14_DAYS
- IP_GDP
- IP_GEMCITABINE_CISPLATIN_EVERY_21_DAYS
- IP_GEMCITABINE_CISPLATIN_EVERY_21_DAYS_LUNG
- IP_GEMCITABINE_CISPLATIN_SPLIT_DOSE
- IP_GEMCITABINE_DOCETAXEL
- IP_GEMCITABINE_1000_EVERY_28_DAYS
- IP_GEMCITABINE_1000_MG_M2_EVERY_21_DAYS
- IP_GEMCITABINE_800_EVERY_7_DAYS
- IP_GEMCITABINE_800_MG_M2_EVERY_21_DAYS
- IP_GEMOX_675_80
- IP_HIDAC_D1_3_5
- IP_HIDAC_D1_3_5_IDARUBICIN
- IP_HIGH_DOSE_METHOTREXATE_LEUCOVORIN_DAY_2
- IP_HYPERCVAD_A_AND_B_ALTERNATING
- IP_ICE
- IP_IFOSFAMIDE_ETOPOSIDE
- IP_INOTUZUMAB_OZOGAMICIN_CONSOLIDATION
- IP_INOTUZUMAB_OZOGAMICIN_INDUCTION
- IP_INTRATHECAL_CHEMOTHERAPY
- IP_LIPOSOMAL_DOXORUBICIN_EVERY_14_DAYS
- IP_LIPOSOMAL_DOXORUBICIN_EVERY_28_DAYS
- IP_LIPOSOMAL_DOXORUBICIN_BEVACIZUMAB
- IP_LIPOSOMAL_IRINOTECAN_LEUCOVORIN_FLUOROURACIL
- IP_MATRIX
- IP_MEC_5_DAYS
- IP_MFOLFOX6_EVERY_14_DAYS
- IP_MFOLFOX6_BEVACIZUMAB_EVERY_14_DAYS
- IP_MINICHOP
- IP_MODIFIED_CYBORDEX
- IP_MODIFIED_FOLFIRINOX_EVERY_2_WEEKS
- IP_MVAC_DOSE_DENSE
- IP_NAB_PACLITAXEL_GEMCITABINE
- IP_NAB_PACLITAXEL_GEMCITABINE_DOSE_REDUCED_EVERY_28_DAYS
- IP_OBINUTUZUMAB_CHLORAMBUCIL_CYCLE_1_ONLY
- IP_OXALIPLATIN_DESENSITIZATION
- IP_PACLITAXEL_DOSE_DENSE_EVERY_21_DAYS
- IP_PACLITAXEL_80_EVERY_21_DAYS
- IP_PACLITAXEL_80_EVERY_28_DAYS
- IP_PACLITAXEL_80_EVERY_7_DAYS
- IP_PAD
- IP_PEMETREXED
- IP_PRALATREXATE
- IP_R_CEOP
- IP_R_CHOP
- IP_R_CVP
- IP_R_DHAP
- IP_R_EPOCH
- IP_R_ESHAP
- IP_R_HIGH_DOSE_METHOTREXATE_LEUCOVORIN_DAY_2
- IP_R_HYPERCVAD_A_AND_B_ALTERNATING
- IP_R_ICE
- IP_R_MINICHOP
- IP_RESEARCH_HILL_CTL_H_43761_CRIMSON_NE
- IP_RESEARCH_INCA34176_357_H_56778_HILL
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_B_FIT_PATIENTS_AGES_18_70_SHAH
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_C_INTENSIFICATION_SHAH
- IP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_E_FIT_PATIENTS_AGES_18_70_SHAH
- IP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_7_3_ARM_SHAH
- IP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_FLAG_IDA_VENETOCLAX_ARM_SHAH
- IP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_FLAG_IDA_ARM_SHAH
- IP_RITUXIMAB_375_WEEKLY
- IP_RITUXIMAB_375_BORTEZOMIB_CYCLE_1_ONLY
- IP_ROMIDEPSIN
- IP_TC
- IP_TECLISTAMAB_CQYV
- IP_TEMOZOLOMIDE_RITUXIMAB
- IP_TIP_GERM_CELL_TUMORS
- IP_TOPOTECAN_DAILY
- IP_TOPOTECAN_EVERY_21_DAYS_D1_D8_D15
- IP_TOPOTECAN_WEEKLY
- IP_TOPOTECAN_BEVACIZUMAB
- IP_TOPOTECAN_BEVACIZUMAB_EVERY_7_DAYS
- IP_TRANSARTERIAL_CHEMOEMBOLIZATION
- IP_VAC_ALTERNATING_WITH_IE
- IP_VAD
- IP_VD_PACE
- IP_VINCRISTINE_EVERY_28_DAYS
- IP_VINORELBINE_EVERY_7_DAYS
- IP_VIP
- IP_VYXEOS_CONSOLIDATION
- IP_VYXEOS_INDUCTION
- IP_XELIRI_EVERY_21_DAYS
- IP_XELIRI_BEVACIZUMAB_EVERY_21_DAYS
- IP_XELOX_EVERY_21_DAYS
- IP_XELOX_BEVACIZUMAB_EVERY_21_DAYS
- IP_OP_BIWEEKLY_TALQUETAMAB_TGVS_TALVEY
- IP_OP_BLINATUMOMAB_MRD_EVERY_42_DAYS
- IP_OP_EMA_CO
- IP_OP_HYPERFRACTIONATED_CYCLOPHOSPHAMIDE
- IP_OP_PRO00037952_CABA_201_002_FOR_IIM_OR_JIIM
- IP_OP_PRO00038144_CABA_201
- IP_OP_PRO00038933_EMN30_ARM_A_TEC_LEN
- IP_OP_PRO00038933_EMN30_ARM_C_TEC
- IP_OP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_C_SHAH
- IP_OP_RESEARCH_PRO00035985_EA9181_NCT04530565_ARM_D_SHAH
- IP_OP_RESEARCH_PRO00037627_GANGULY_P_BCMA_ALL01_OPEN_LABEL_PHASE_I_ARM_P1
- IP_OP_RESEARCH_PRO00037627_GANGULY_P_BCMA_ALL01_OPEN_LABEL_PHASE_I_ARM_P1.5
- IP_OP_RESEARCH_PRO00037922_GANGULY_PFIZER_C1071032_OPEN_LABEL_ELRANATAMAB_ARM_A
- IP_OP_RESEARCH_PRO00038139_IOV_LUN_202_TREATMENT_AND_POST_TREATMENT_PERIOD_ZHANG
- IP_OP_RESEARCH_PRO00038239_NCT06413498_ANITOCABTAGENE_AUTOLEUCEL_ARM
- IP_OP_RESEARCH_PRO00038439_AC220_168_PLAN_A_INDUCTION_WITH_7_3_CYCLES_1_AND_2_WITH_CYTARABINE_DAUNORUBICIN
- IP_OP_RESEARCH_PRO00038439_AC220_168_PLAN_B_INDUCTION_WITH_7_3_CYCLES_1_AND_2_WITH_CYTARABINE_IDARUBICIN
- IP_OP_RESEARCH_PRO00038439_AC220_168_PLAN_C_INDUCTION_WITH_7_3_CYCLE_1_FOLLOWED_BY_5_2_CYCLE_2_CYTARABINE_DAUNORUBICIN
- IP_OP_RESEARCH_PRO00038439_AC220_168_PLAN_D_INDUCTION_WITH_7_3_CYCLE_1_FOLLOWED_BY_5_2_CYCLE_2_CYTARABINE_IDARUBICIN
- IP_OP_RESEARCH_PRO00038439_AC220_168_PLAN_E_CONSOLIDATION
- IP_OP_RESEARCH_PRO00040263_NKX019_102_GUEVARA_PHASE_1_2_STUDY_FOR_PATIENTS_WITH_AUTOIMMUNE_DISEASE
- IP_OP_RSH_CILESTE_H_47906
- IP_OP_RSH_PRO00038180_PRATH_JANX007_SCREENING
- IP_OP_RSH_PRO00038180_PRATH_JANX007_STEP_DOSE_SCHEDULE_B
- IP_OP_RSH_PRO00038180_PRATH_JANX007_STEPPED_DOSE_SCHEDULE_A
- IP_OP_RSH_PRO00041409_GANGULY_MAJESTEC_7_ARM_A
- IP_OP_RSH_PRO00041409_GANGULY_MAJESTEC_7_ARM_B
- IP_OP_RSH_PRO00041409_GANGULY_MAJESTEC_7_ARM_C
- IP_OP_RSH_PRO00041409_GANGULY_MAJESTEC_7_SCREENING
- IP_OP_RSH_PRO00042030_ZHANG_MK_6070_003_ARM_1_PART_A_AND_B
- IP_OP_RSH_PRO00042030_ZHANG_MK_6070_003_ARM_2_PART_A_AND_B
- IP_OP_RSH_PRO00042030_ZHANG_MK_6070_003_ARM_3_PART_B
- IP_OP_TARLATAMAB_DLLE
- IP_OP_TEBENTAFUSP_TEBN
- IP_OP_WEEKLY_TALQUETAMAB_TGVS_TALVEY
- LIPOSOMAL_DOXORUBICIN_EVERY_14_DAYS
- MFOLFOX_TRASTUZUMAB_EVERY_14_DAYS
- NHL_IP_BENDAMUSTINE_120_RITUXIMAB_375_START_ON_DAY_2
- NHL_IP_BENDAMUSTINE_90_RITUXIMAB_375_START_ON_DAY_1
- NHL_IP_BENDAMUSTINE_90_RITUXIMAB_375_START_ON_DAY_2
- NIVOLUMAB_HYALURONIDASE_FLAT_DOSE_EVERY_14_DAYS
- NIVOLUMAB_HYALURONIDASE_FLAT_DOSE_EVERY_28_DAYS
- NOGAPENDEKIN_ALFA_INBAKICEPT_PMLN_ANKTIVA_BCG_BACILLUS_CALMETTE_GUERIN_EVERY_7_DAYS_CYCLES_INDUCTION
- NOGAPENDEKIN_ALFA_INBAKICEPT_PMLN_ANKTIVA_BCG_BACILLUS_CALMETTE_GUERIN_MAINTENANCE
- OP_ABVD
- OP_ADO_TRASTUZUMAB_EMTANSINE_EVERY_21_DAYS
- OP_AIM
- OP_ALEMTUZUMAB
- OP_AMIVANTAMAB_VMJW
- OP_AMIVANTAMAB_CARBOPLATIN_AUC_5_PEMETREXED_CYCLES_1_TO_4
- OP_AMIVANTAMAB_PEMETREXED_MAINTENANCE
- OP_APML4_SECOND_CONSOLIDATION
- OP_ARSENIC_TRIOXIDE_CONSOLIDATION
- OP_ARSENIC_TRIOXIDE_INDUCTION
- OP_ARSENIC_TRIOXIDE_MAINTENANCE_EVERY_28_DAYS
- OP_ATEZOLIZUMAB_EVERY_21_DAYS
- OP_ATEZOLIZUMAB_BEVACIZUMAB_EVERY_21_DAYS
- OP_ATEZOLIZUMAB_1680_MG_EVERY_28_DAYS
- OP_AVD_BRENTUXIMAB
- OP_AVELUMAB_EVERY_14_DAYS
- OP_AYA_COURSE_1_REMISSION_INDUCTION
- OP_AYA_COURSE_1A_EXTENDED_REMISSION_INDUCTION
- OP_AYA_COURSE_2_REMISSION_CONSOLIDATION
- OP_AYA_COURSE_3_INTERIM_MAINTENANCE
- OP_AYA_COURSE_4_DELAYED_INTENSIFICATION
- OP_AYA_COURSE_5_MAINTENANCE_THERAPY
- OP_AZACITIDINE_5_DAYS
- OP_AZACITIDINE_7_DAYS
- OP_BACILLUS_CALMETTE_GUERIN_INDUCTION_EVERY_7_DAYS
- OP_BELANTAMAB_MAFODOTIN_BLMF_EVERY_21_DAYS
- OP_BENDAMUSTINE_OBINUTUZUMAB_NHL_EVERY_28_DAYS
- OP_BENDAMUSTINE_RITUXIMAB_DAY_1_START_CLL
- OP_BEP
- OP_BEVACIZUMAB_EVERY_14_DAYS
- OP_BEVACIZUMAB_EVERY_21_DAYS
- OP_BLANK_CHEMOTHERAPY_PLAN_EVERY_21_DAYS
- OP_BORTEZOMIB_EVERY_21_DAYS
- OP_BORTEZOMIB_EVERY_7_DAYS
- OP_BORTEZOMIB_MAINTENANCE_EVERY_14_DAYS
- OP_BRENTUXIMAB_VEDOTIN_EVERY_21_DAYS
- OP_CABAZITAXEL_EVERY_21_DAYS
- OP_CAGT_AUTOLOGOUS_MOBILIZATION_HIGH_DOSE_CYCLOPHOSPHAMIDE
- OP_CAGT_AUTOLOGOUS_SCT_IV_RITUXIMAB_BEAM_R
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_TISAGENLECLEUCEL_ACUTE_LYMPHOCYTIC_LEUKEMIA_ALL
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_TISAGENLECLEUCEL_DIFFUSE_LARGE_B_CELL_LYMPHOMA_DLBCL
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_LYMPHODEPLETION_MAGENTA
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_LYMPHODEPLETION_MB105_201
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_LYMPHODEPLETION_RELY_30
- OP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_AXICABTAGENE_CILOLEUCEL_DIFFUSE_LARGE_B_CELL_LYMPHOMA_DLBCL
- OP_CAGT_R_IE
- OP_CAP
- OP_CAPEOX_EVERY_21_DAYS
- OP_CAPEOX_ZOLBETUXIMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_2_PACLITAXEL_D1D8D15_EVERY_28_DAYS
- OP_CARBOPLATIN_AUC_4_GEMCITABINE_BEVACIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_PACLITAXEL_DOSTARLIMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_WEEKLY_PACLITAXEL_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_NAB_PACLITAXEL_WEEKLY_PEMBROLIZUMAB_X_4_CYCLES_FOLLOWED_BY_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_NAB_PACLITAXEL_D1D8D15_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_2_PACLITAXEL_WITH_CONCURRENT_THORACIC_RT_EVERY_7_DAYS
- OP_CARBOPLATIN_AUC_2_WITH_CONCURRENT_RADIATION_EVERY_7_DAYS
- OP_CARBOPLATIN_AUC_4_CABAZITAXEL_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_ETOPOSIDE_ATEZOLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_FLUOROURACIL_CADD_PEMBROLIZUMAB_HEAD_AND_NECK_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_GEMCITABINE_NIVOLUMAB_LUNG_CANCER_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_BEVACIZUMAB_ATEZOLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_BEVACIZUMAB_GYNECOLOGIC_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_NIVOLUMAB_LUNG_CANCER_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_GYNECOLOGIC_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_LUNG_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PEMETREXED_BEVACIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_WEEKLY_PACLITAXEL_BEVACIZUMAB_DOSE_DENSE_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_WEEKLY_PACLITAXEL_DOSE_DENSE_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_6_PACLITAXEL_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_AUC_5_PACLITAXEL_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_DOCETAXEL_EVERY_21_DAYS
- OP_CARBOPLATIN_ETOPOSIDE_EVERY_21_DAYS
- OP_CARBOPLATIN_GEMCITABINE_D1D8_EVERY_21_DAYS
- OP_CARBOPLATIN_LIPOSOMAL_DOXORUBICIN
- OP_CARBOPLATIN_PEMETREXED_EVERY_21_DAYS
- OP_CARBOPLATIN_PEMETREXED_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_WEEKLY_CETUXIMAB_EVERY_21_DAYS
- OP_CARBOPLATIN_D1D8_GEMCITABINE_D1D8_EVERY_21_DAYS
- OP_CARFILZOMIB_INITIAL_AND_MAINTENANCE
- OP_CARFILZOMIB_INITIAL_CYCLE
- OP_CARFILZOMIB_MAINTENANCE
- OP_CARFILZOMIB_WEEKLY
- OP_CARMUSTINE_BEVACIZUMAB_EVERY_42_DAYS
- OP_CEMIPLIMAB_EVERY_21_DAYS
- OP_CETUXIMAB_EVERY_14_DAYS
- OP_CETUXIMAB_EVERY_7_DAYS
- OP_CETUXIMAB_PEMBROLIZUMAB_EVERY_42_DAYS
- OP_CHOEP_EVERY_21_DAYS
- OP_CHOP
- OP_CISPLATIN_EVERY_21_DAYS
- OP_CISPLATIN_DOCETAXEL_EVERY_21_DAYS
- OP_CISPLATIN_DOCETAXEL_5FU
- OP_CISPLATIN_DOXORUBICIN_EVERY_21_DAYS
- OP_CISPLATIN_ETOPOSIDE_EVERY_21_DAYS
- OP_CISPLATIN_ETOPOSIDE_WITH_CONCURRENT_RADIATION_SCLC_NECC_EVERY_21_DAYS
- OP_CISPLATIN_ETOPOSIDE_WITH_CONCURRENT_RADIATION_THORACIC_NSCLC_EVERY_28_DAYS
- OP_CISPLATIN_GEMCITABINE_EVERY_21_DAYS
- OP_CISPLATIN_GEMCITABINE_PEMBROLIZUMAB_NSCLC_EVERY_21_DAYS
- OP_CISPLATIN_IRINOTECAN_D1D8D15_EVERY_21_DAYS
- OP_CISPLATIN_PACLITAXEL_EVERY_21_DAYS
- OP_CISPLATIN_PACLITAXEL_BEVACIZUMAB_EVERY_21_DAYS
- OP_CISPLATIN_PEMETREXED
- OP_CISPLATIN_PEMETREXED_NIVOLUMAB_EVERY_21_DAYS
- OP_CISPLATIN_PEMETREXED_PEMBROLIZUMAB_NSCLC_EVERY_21_DAYS
- OP_CISPLATIN_PEMETREXED_WITH_CONCURRENT_RADIATION_EVERY_21_DAYS
- OP_CISPLATIN_VINORELBINE_EVERY_21_DAYS
- OP_CISPLATIN_D1D8_GEMCITABINE_D1D8_EVERY_28_DAYS
- OP_CISPLATIN_W_CONCURRENT_RT_EVERY_7_DAYS
- OP_CISPLATIN_W_CONCURRENT_RT_EVERY_21_DAYS
- OP_CISPLATIN_SPLIT_DOSE_IRINOTECAN_EVERY_21_DAYS
- OP_CLADRIBINE_DAILY
- OP_CLADRIBINE_WEEKLY
- OP_CLOFARABINE_CYTARABINE
- OP_CMF
- OP_CVP
- OP_CYBORDEX
- OP_CYCLOPHOSPHAMIDE_VINCRISTINE_MERCAPTOPURINE_CYTARABINE_PEGASPARGASE
- OP_DARATUMUMAB
- OP_DARATUMUMAB_BORTEZOMIB_DEXAMETHASONE
- OP_DARATUMUMAB_HYALURONIDASE_DARZALEX_FASPRO
- OP_DARATUMUMAB_HYALURONIDASE_FIHJ_BORTEZOMIB_DEXAMETHASONE_GRIFFIN_TRIAL
- OP_DARATUMUMAB_HYALURONIDASE_FIHJ_CARFILZOMIB_DEXAMETHASONE_CANDOR_TRIAL_EVERY_28_DAYS
- OP_DARATUMUMAB_HYALURONIDASE_FIHJ_WEEKLY_BORTEZOMIB_LENALIDOMIDE_DEXAMETHASONE_PERSEUS
- OP_DARZALEX_FASPRO_CYBORDEX_ANDROMEDA_PROTOCOL
- OP_DARZALEX_FASPRO_CYBORDEX_LYRA_PROTOCOL
- OP_DATOPOTAMAB_DERUXTECAN_EVERY_21_DAYS
- OP_DECITABINE_EVERY_28_DAYS
- OP_DOCETAXEL_EVERY_21_DAYS
- OP_DOCETAXEL_CYCLOPHOSPHAMIDE_EVERY_21_DAYS
- OP_DOXORUBICIN_CYCLOPHOSPHAMIDE_EVERY_21_DAYS
- OP_DOXORUBICIN_CYCLOPHOSPHAMIDE_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_DOXORUBICIN_CYCLOPHOSPHAMIDE_DOSE_DENSE_EVERY_14_DAYS
- OP_DOXORUBICIN_75_MG_M2_BOLUS_IFOSFAMIDE_10_G_M2_OVER_4_DAYS_MESNA_CIV
- OP_DOXORUBICIN_75_MG_M2_BOLUS_IFOSFAMIDE_10_G_M2_OVER_5_DAYS_MESNA_BOLUS
- OP_DOXORUBICIN_75_MG_M2_CIV_IFOSFAMIDE_10_G_M2_OVER_5_DAYS_MESNA_BOLUS
- OP_DOXORUBICIN_TRABECTEDIN_INDUCTION
- OP_DURVALUMAB_10_MG_KG_EVERY_14_DAYS
- OP_DURVALUMAB_1500_MG_EVERY_28_DAYS
- OP_DURVALUMAB_GEMCITABINE_CISPLATIN_X_8_CYCLES_EVERY_21_DAYS_THEN_DURVALUMAB_MAINTENANCE_EVERY_28_DAYS_CHOLANGIOCARCINOMA
- OP_DVD_LOW_DOSE
- OP_DVD_R
- OP_ENFORTUMAB_VEDOTIN_EVERY_28_DAYS
- OP_ENFORTUMAB_VEDOTIN_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_EPIRUBICIN_CYCLOPHOSPHAMIDE_EVERY_21_DAYS
- OP_ERIBULIN_D1D8_EVERY_21_DAYS
- OP_FAC_EVERY_21_DAYS
- OP_FAM_TRASTUZUMAB_DERUXTECAN_EVERY_21_DAYS
- OP_FLA
- OP_FLOT_EVERY_14_DAYS
- OP_FLUDARABINE_CYCLOPHOSPHAMIDE_RITUXIMAB
- OP_FLUOROURACIL_MITOMYCIN_WITH_CONCURRENT_RADIATION_EVERY_28_DAYS
- OP_FLUOROURACIL_WITH_CONCURRENT_RADIATION_EVERY_7_DAYS
- OP_FOLFIRI_EVERY_14_DAYS
- OP_FOLFIRI_BEVACIZUMAB_EVERY_14_DAYS
- OP_FOLFIRI_CETUXIMAB_EVERY_14_DAYS
- OP_FOLFIRI_PANITUMUMAB_EVERY_14_DAYS
- OP_FOLFIRI_RAMUCIRUMAB_EVERY_14_DAYS
- OP_FOLFOX_WITH_RADIATION_ESOPHAGEAL_CANCER_EVERY_14_DAYS
- OP_GDP
- OP_GEMCITABINE_CISPLATIN_GALLBLADDER
- OP_GEMCITABINE_DOCETAXEL_EVERY_21_DAYS
- OP_GEMCITABINE_OXALIPLATIN_EVERY_14_DAYS
- OP_GEMCITABINE_VINORELBINE_DOXORUBICIN_LIPOSOMAL
- OP_GEMCITABINE_D1D8D15_EVERY_28_DAYS
- OP_IFOSFAMIDE_XRT
- OP_IMETELSTAT_RYTELO
- OP_INOTUZUMAB_OZOGAMICIN_CONSOLIDATION
- OP_INOTUZUMAB_OZOGAMICIN_INDUCTION
- OP_INTRATHECAL_CHEMOTHERAPY
- OP_INTRAVESICAL_GEMCITABINE_DOCETAXEL_PLAN_MONTHLY_MAINTENANCE_FOR_1_YEAR
- OP_IPILIMUMAB_NIVOLUMAB_EVERY_21_DAYS
- OP_IPILIMUMAB_NIVOLUMAB_NSCLC_EVERY_42_DAYS
- OP_IRINOTECAN_CETUXIMAB_EVERY_14_DAYS
- OP_IRINOTECAN_PANITUMUMAB_EVERY_14_DAYS
- OP_IROX
- OP_ISATUXIMAB_CARFILZOMIB_DEXAMETHASONE_IKEMA
- OP_IXABEPILONE
- OP_KEYNOTE_A18
- OP_LIPOSOMAL_DOXORUBICIN_EVERY_28_DAYS
- OP_LIPOSOMAL_DOXORUBICIN_BEVACIZUMAB_EVERY_28_DAYS
- OP_LIPOSOMAL_IRINOTECAN_FLUOROURACIL_EVERY_14_DAYS
- OP_LONCASTUXIMAB_TESIRINE_LPYL_INITIAL_AND_MAINTENANCE_DOSE
- OP_LOW_DOSE_CYTARABINE_10_DAYS
- OP_LURBINECTEDIN_EVERY_21_DAYS
- OP_MARGETUXIMAB_ERIBULIN_EVERY_21_DAYS
- OP_MARGETUXIMAB_GEMCITABINE_EVERY_21_DAYS
- OP_MARGETUXIMAB_VINORELBINE_EVERY_21_DAYS
- OP_MFOLFOX6_EVERY_14_DAYS
- OP_MFOLFOX6_ZOLBETUXIMAB_EVERY_14_DAYS
- OP_MFOLFOX6_BEVACIZUMAB_EVERY_14_DAYS
- OP_MFOLFOX6_CETUXIMAB_EVERY_14_DAYS
- OP_MFOLFOX6_NIVOLUMAB_EVERY_14_DAYS
- OP_MFOLFOX6_PANITUMUMAB_EVERY_14_DAYS
- OP_MINICHOP
- OP_MIRVETUXIMAB_SORAVTANSINE_GYNX_EVERY_21_DAYS
- OP_MITOMYCIN_GEL_FOR_PYELOCALICEAL_INSTILLATION_INITIATION_EVERY_7_DAYS
- OP_MITOXANTRONE_PROSTATE_CANCER_EVERY_21_DAYS
- OP_MODIFIED_CYBORDEX
- OP_MODIFIED_FOLFIRINOX_EVERY_2_WEEKS
- OP_MOGAMULIZUMAB_EVERY_28_DAYS
- OP_MVAC_DOSE_DENSE
- OP_NAB_PACLITAXEL_EVERY_21_DAYS
- OP_NAB_PACLITAXEL_D1D8D15_GEMCITABINE_D1D8D15_EVERY_28_DAYS
- OP_NADOFARAGENE_FIRADENOVEC_ADSTILADRIN
- OP_NIVOLUMAB_3_MG_KG_EVERY_14_DAYS
- OP_NIVOLUMAB_AND_RELATLIMAB_EVERY_28_DAYS
- OP_OBINUTUZUMAB_EVERY_28_DAYS
- OP_PACLITAXEL_WEEKLY_EVERY_7_DAYS
- OP_PACLITAXEL_DOSE_DENSE_EVERY_14_DAYS
- OP_PANITUMUMAB_EVERY_14_DAYS
- OP_PEMBROLIZUMAB_200_MG_EVERY_21_DAYS
- OP_PEMBROLIZUMAB_400_MG_EVERY_42_DAYS
- OP_PEMETREXED_EVERY_21_DAYS
- OP_POLATUZUMAB_BENDAMUSTINE_RITUXIMAB_NHL_EVERY_21_DAYS
- OP_POMP
- OP_PRALATREXATE
- OP_PRO00037422_LU22_SCREENING
- OP_PRO00037422_LU22_TREATMENT
- OP_PRO00038124_ARM_1_DATO_DXD_DURVALUMAB_NEOADJUVANT_SETTING_EXPERIMENTAL
- OP_PRO00038124_ARM_1_DURVALUMAB_1120_MG_CHEMOTHERAPY_ADJUVANT_SETTING_EXPERIMENTAL
- OP_PRO00038124_ARM_1_DURVALUMAB_1120_MG_ADJUVANT_SETTING_EXPERIMENTAL
- OP_PRO00038124_ARM_2_OP_AC_PEMBROLIZUMAB_NEOADJUVANT_SETTING_CONTROL
- OP_PRO00038124_ARM_2_OP_CARBOPLATIN_AUC_5_WEEKLY_PACLITAXEL_PEMBROLIZUMAB_NEOADJUVANT_SETTING_CONTROL
- OP_PRO00038124_ARM_2_PEMBROLIZUMAB_CHEMOTHERPAY_ADJUVANT_SETTING_CONTROL
- OP_PRO00038124_ARM_2_PEMBROLIZUMAB_ADJUVANT_SETTING_CONTROL
- OP_PRO00038124_SCREENING
- OP_PRO00038327_SPI_BEL_301_GROUP_2B_PRALATREXATE_30_MG_M2_COP
- OP_PRO00038327_SPI_BEL_301_GROUP_1A_BEL_CHOP_BELINOSTAT_600_MG_M2
- OP_PRO00038327_SPI_BEL_301_GROUP_1B_BEL_CHOP_BELINOSTAT_1000_MG_M2
- OP_PRO00038327_SPI_BEL_301_GROUP_2A_PRALATREXATE_20_MG_M2_COP
- OP_PRO00038327_SPI_BEL_301_GROUP_3_CONTROL_ARM_CHOP
- OP_PRO00038327_SPI_BEL_301_SCREENING
- OP_PRO00038456_YTB323
- OP_PRO00038487_PRISM_1_PLAN_3_QUEMLICLUSTAT_PLACEBO_ONLY_CYCLES_13_24
- OP_PRO00038487_PRISM_1_SCREENING
- OP_PRO00038487_PRISM_1_PLAN_1_ALL_ARMS_QUEMLICLUSTAT_PLACEBO_NP_GEM_CYCLES_1_TO_12
- OP_PRO00038487_PRISM_1_PLAN_2_NP_GEM_CYCLES_13_24
- OP_PRO00038634_WO44263_BIOMARKER_SCREENING
- OP_PRO00038634_WO44263_INDUCTION_SCREENING
- OP_PRO00038634_WO44263_INDUCTION_THERAPY_PLAN_A
- OP_PRO00038634_WO44263_INDUCTION_THERAPY_PLAN_B
- OP_PRO00038634_WO44263_INDUCTION_THERAPY_PLAN_C
- OP_PRO00038634_WO44263_MAINTENANCE_SCREENING
- OP_PRO00038634_WO44263_MAINTENANCE_THERAPY_PLAN_D
- OP_PRO00038933_EMN30_ARM_B_LEN
- OP_PRO00038933_EMN30_SCREENING
- OP_PRO00040430_SMT112_3007_SCREENING_ZHANG
- OP_PRO00040430_SMT112_3007_ZHANG
- OP_PROCARBAZINE_LOMUSTINE_VINCRISTINE
- OP_R_CEOP
- OP_R_CHOP
- OP_R_CVP
- OP_R_EPOCH
- OP_R_ICE
- OP_R_MINICHOP
- OP_RAMUCIRUMAB_EVERY_14_DAYS
- OP_RAMUCIRUMAB_DOCETAXEL_EVERY_21_DAYS
- OP_RAMUCIRUMAB_PACLITAXEL_EVERY_28_DAYS
- OP_RESEARCH_CABAL2_H_56523
- OP_RESEARCH_CTL_BESTA_H_46862
- OP_RESEARCH_CTL_H_43516_CARMEN_PROCURMENT
- OP_RESEARCH_H_43405_VISTA_INFUSION
- OP_RESEARCH_H_43405_VISTA_PROCUREMENT_ORDERS
- OP_RESEARCH_H_44843_TETRAVI_STUDY
- OP_RESEARCH_H_47739_BAT_IT_FOLLOW_UP
- OP_RESEARCH_H47561_MSC_COVID_19
- OP_RESEARCH_INCA34176_357_H_56778_ELIGIBILITY_SCREENING_AND_CONSENT_HILL
- OP_RESEARCH_INCA34176_357_H_56778_HILL
- OP_RESEARCH_PRO00021286_KAMAT_NRG_GY009_ARM_2
- OP_RESEARCH_PRO00026229_ABDELRAHIM_NAPOLI_3_ARM_1
- OP_RESEARCH_PRO00028602_INTEGRAL_ALL_PATIENTS
- OP_RESEARCH_PRO00028925_FULVESTRANT_PLUS_ABEMACICLIB_WITH_FULVESTRANT_RUN_IN_CHANG
- OP_RESEARCH_PRO00028925_FULVESTRANT_PLUS_ABEMACICLIB_WITHOUT_FULVESTRANT_RUN_IN_CHANG
- OP_RESEARCH_PRO00029685_A011801_JAIN
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_BASELINE_ASSESSMENTS_NIRAVATH
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_NIRAVATH
- OP_RESEARCH_PRO00030489_HMCC_BR22_001_SCREENING_ASSESSMENTS_NIRAVATH
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_1_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_2_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_3_HAQUE
- OP_RESEARCH_PRO00031037_NCT04513717_ARM_4_HAQUE
- OP_RESEARCH_PRO00032239_ML43352_ABDELRAHIM
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_ARM_1_STEP_2
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_ARM_2_STEP_2
- OP_RESEARCH_PRO00035654_NCT04071457_GANGULY_PRE_REGISTRATION_STEP_2
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_MAINTENANCE_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_PRIOR_TO_ALLOGENIC_HCT
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_0_PRE_REGISTRATION_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_1_REGISTRATION_PRE_INDUCTION_ARM_A_STEP_2_RANDOMIZATION_SHAH
- OP_RESEARCH_PRO00035985_EA9181_NCT04530565_STEP_3_PRE_REGISTRATION_SHAH
- OP_RESEARCH_PRO00036193_ARM_A_MMY3002_GANGULY
- OP_RESEARCH_PRO00036193_ARM_B_MMY3002_GANGULY
- OP_RESEARCH_PRO00036193_ARM_C_MMY3002_GANGULY
- OP_RESEARCH_PRO00036218_BAYER_21516_EFSTATHIOU
- OP_RESEARCH_PRO00036449_RAMSHESH_NRG_BR007_ENDOCRINE_THERAPY_RT_PHASE_III_ARM_1
- OP_RESEARCH_PRO00036449_RAMSHESH_NRG_BR007_ENDOCRINE_THERAPY_ONLY_PHASE_III_ARM_2
- OP_RESEARCH_PRO00036449_RAMSHESH_NRG_BR007_PHASE_III_SCREENING
- OP_RESEARCH_PRO00036844_EFSTATHIOU_AZD5305_WITH_ABIRATERONE_ACETATE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_2
- OP_RESEARCH_PRO00036844_EFSTATHIOU_AZD5305_WITH_DAROLUTAMIDE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_3
- OP_RESEARCH_PRO00036844_EFSTATHIOU_AZD5305_WITH_ENZALUTAMIDE_OPEN_LABEL_PHASE_I_IIA_PETRANHA_ARM_1
- OP_RESEARCH_PRO00036844_EFSTATHIOU_AZD5305_WITH_HORMONAL_AGENTS_OPEN_LABEL_PHASE_I_IIA_PETRANHA_SCREENING
- OP_RESEARCH_PRO00036985_NCT05132504_POST_SURGERY_ESNAOLA
- OP_RESEARCH_PRO00036985_NCT05132504_PRE_SURGERY_ESNAOLA
- OP_RESEARCH_PRO00036985_NCT05132504_SCREENING_ESNAOLA
- OP_RESEARCH_PRO00037014_SHAH_BMS_CA055_026_AZACITIDINE_RANDOMIZED_SCREENING
- OP_RESEARCH_PRO00037679_ZHANG_EA5182_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_SCREENING
- OP_RESEARCH_PRO00037679_ZHANG_EA5182_OSIMERTINIB_AZD9291_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_ARM_A
- OP_RESEARCH_PRO00037679_ZHANG_EA5182_OSIMERTINIB_AZD9291_WITH_BEVACIZUMAB_FOR_PATIENTS_WITH_METASTATIC_EGFR_MUTANT_NON_SMALL_CELL_LUNG_CANCER_NSCLC_RANDOMIZED_ARM_B
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1B_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1B_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_1C
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2A_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2A_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2B_Q2W_EVERY_2_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_PART_2B_Q4W_EVERY_4_WEEKS
- OP_RESEARCH_PRO00037722_ABDELRAHIM_CA052002_PHASE1_2_SCREENING
- OP_RESEARCH_PRO00037762_HMCC_HM22_001_ATRA_ARM_1
- OP_RESEARCH_PRO00037762_HMCC_HM22_001_ATRA_SCREENING_BASELINE
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_ARM_A
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_ARM_B
- OP_RESEARCH_PRO00037808_D361DC00001_SUN_SCREENING
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_ARM_A
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_ARM_B
- OP_RESEARCH_PRO00037831_ML44719_ABDELRAHIM_SCREENING
- OP_RESEARCH_PRO00037834_IDE196_002_IND_143026_MAQSOOD_PHASE_2A_ARM_1
- OP_RESEARCH_PRO00037834_IDE196_002_IND_143026_MAQSOOD_PHASE_2A_ARM_2
- OP_RESEARCH_PRO00037834_IDE196_002_IND_143026_MAQSOOD_PHASE_2A_CHEMOTHERAPY_ARM_3_COMPARATOR_ARM
- OP_RESEARCH_PRO00037834_IDE196_002_IND_143026_MAQSOOD_PHASE_2B_AND_3_CHEMOTHERAPY_ARM_2_COMPARATOR_ARM
- OP_RESEARCH_PRO00037834_IDE196_002_IND_143026_MAQSOOD_SCREENING
- OP_RESEARCH_PRO00037866_DB_1303_O_3002_NIRAVATH_ARM_1
- OP_RESEARCH_PRO00037866_DB_1303_O_3002_NIRAVATH_ARM_2_NAB_PACLITAXEL
- OP_RESEARCH_PRO00037866_DB_1303_O_3002_NIRAVATH_ARM_2_PACLITAXEL
- OP_RESEARCH_PRO00037866_DB_1303_O_3002_NIRAVATH_SCREENING
- OP_RESEARCH_PRO00037870_KAUSHIK_ADJUVANT_V940_MRNA_4157_RANDOMIZED_DOUBLE_BLIND_PHASE_2
- OP_RESEARCH_PRO00037922_GANGULY_PFIZER_C1071032_ELOTUZUMAB_POMALIDOMIDE_DEXAMETHASONE_EPD_ARM_B
- OP_RESEARCH_PRO00037922_GANGULY_PFIZER_C1071032_MAGNETISMM_32_KD_ARM_B
- OP_RESEARCH_PRO00037922_GANGULY_PFIZER_C1071032_OPEN_LABEL_SCREENING
- OP_RESEARCH_PRO00037933_MERCK_MK_2870_005_GOG_3095_ARM_1
- OP_RESEARCH_PRO00037933_MERCK_MK_2870_005_GOG_3095_ARM_2_DOXORUBICIN
- OP_RESEARCH_PRO00037933_MERCK_MK_2870_005_GOG_3095_ARM_2_PACLITAXEL
- OP_RESEARCH_PRO00037983_NCT05899608_SCREENING_ZHANG
- OP_RESEARCH_PRO00037983_NCT05899608_WITH_CARBOPLATIN_AUC_6_ABRAXANE_ZHANG_FOR_SQUAMOUS_HISTOLOGY
- OP_RESEARCH_PRO00037983_NCT05899608_WITH_CARBOPLATIN_AUC_6_PACLITAXEL_ZHANG_FOR_SQUAMOUS_HISTOLOGY
- OP_RESEARCH_PRO00037983_NCT05899608_WITH_CARBOPLATIN_AUC_5_PEMETREXED_FOR_NON_SQUAMOUS_HISTOLOGY
- OP_RESEARCH_PRO00037985_ZHANG_J3M_MC_JZQB_BASELINE_SCREENING
- OP_RESEARCH_PRO00037985_ZHANG_J3M_MC_JZQB_NON_SMALL_CELL_LUNG_ARM_B
- OP_RESEARCH_PRO00037985_ZHANG_J3M_MC_JZQB_PRE_SCREENING
- OP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_AZACITIDINE_ARM_SHAH
- OP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_DECITABINE_ARM_SHAH
- OP_RESEARCH_PRO00038056_HMCC_HM24_001_5HMC_SCREENING_and_BASELINE_SHAH
- OP_RESEARCH_PRO00038139_IOV_LUN_202_PRE_TREATMENT_PERIOD_TUMOR_HARVEST_BASELINE_ZHANG
- OP_RESEARCH_PRO00038139_IOV_LUN_202_SCREENING_AND_ENROLLMENT_PERIOD_PERIOD_ZHANG
- OP_RESEARCH_PRO00038188_NCT06208150_ARM_A
- OP_RESEARCH_PRO00038188_NCT06208150_ARM_B
- OP_RESEARCH_PRO00038188_NCT06208150_ARM_C_EPD
- OP_RESEARCH_PRO00038188_NCT06208150_ARM_C_PVD
- OP_RESEARCH_PRO00038188_NCT06208150_SCREENING
- OP_RESEARCH_PRO00038209_A062102_GANGULY_IBERDOMIDE
- OP_RESEARCH_PRO00038209_A062102_GANGULY_SCREENING
- OP_RESEARCH_PRO00038239_NCT06413498_BRIDGE_THERAPY_MANDATORY_PROCEDURES_TO_BE_PERFORMED_ON_D1_OF_C1
- OP_RESEARCH_PRO00038239_NCT06413498_DPD
- OP_RESEARCH_PRO00038239_NCT06413498_KD
- OP_RESEARCH_PRO00038239_NCT06413498_KDD
- OP_RESEARCH_PRO00038239_NCT06413498_LEUKAPHERESIS
- OP_RESEARCH_PRO00038239_NCT06413498_SCREENING_AND_RE_SCREENING
- OP_RESEARCH_PRO00038278_DURVALUMAB_BEVACIZUMAB_TARE_PROTOCOL
- OP_RESEARCH_PRO00038278_DURVALUMAB_BEVACIZUMAB_SCREENING_BASELINE
- OP_RESEARCH_PRO00038285_NALIRIFOX_BASELINE_DAYS_7_TO_1
- OP_RESEARCH_PRO00038285_NALIRIFOX_PROTOCOL
- OP_RESEARCH_PRO00038285_NALIRIFOX_SCREENING_DAYS_28_TO_7
- OP_RESEARCH_PRO00038299_NIRAVATH_BEAMICON_BCGC_1_COHORT_A
- OP_RESEARCH_PRO00038299_NIRAVATH_BEAMICON_BCGC_1_COHORT_B
- OP_RESEARCH_PRO00038299_NIRAVATH_BEAMICON_BCGC_1_COHORT_C
- OP_RESEARCH_PRO00038299_NIRAVATH_BEAMICON_BCGC_1_SCREENING
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_DARATUMUMAB_FOR_NEW_AL_AMYLOIDOSIS_MAINTENANCE
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_FOR_NEW_AL_AMYLOIDOSIS_CONSOLIDATION_ARM_1
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_FOR_NEW_AL_AMYLOIDOSIS_INDUCTION
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_REGISTRATION_PRIOR_TO_STEP_1
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_REGISTRATION_PRIOR_TO_STEP_2
- OP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_REGISTRATION_PRIOR_TO_STEP_3
- OP_RESEARCH_PRO00038342_ALE1001_SHAH_PHASE_2
- OP_RESEARCH_PRO00038342_ALE1001_SHAH_SCREENING_PHASE_2
- OP_RESEARCH_PRO00038369_HMCC_GI24_001_ARM_1
- OP_RESEARCH_PRO00038369_HMCC_GI24_001_ARM_2
- OP_RESEARCH_PRO00038369_HMCC_GI24_001_SCREENING_BASELINE
- OP_RESEARCH_PRO00038439_AC220_168_ALLOGENEIC_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
- OP_RESEARCH_PRO00038439_AC220_168_ASSESSMENTS_LABS_PROCEDURES_FOR_LONG_TERM_FOLLOW_UP
- OP_RESEARCH_PRO00038439_AC220_168_PLAN_F_MAINTENANCE
- OP_RESEARCH_PRO00038439_AC220_168_SCREENING_BASELINE
- OP_RESEARCH_PRO00038457_ABLE_22_ARM_1_NADOFARAGENE_FIRADENOVEC_OPTIONAL_TREATMENT_FROM_MONTH_12_UP_TO_MONTH_24
- OP_RESEARCH_PRO00038457_ABLE_22_ARM_1_NADOFARAGENE_FIRADENOVEC_PLANNED_TREATMENT_PERIOD_OF_ALL_SUBJECTS_UP_TO_MONTH_12
- OP_RESEARCH_PRO00038457_ABLE_22_SATKUNASIVAM_OPTIONAL_TREATMENT_PERIOD_FROM_MONTH_12_UP_TO_24
- OP_RESEARCH_PRO00038457_ABLE_22_SATKUNASIVAM_PLANNED_TREATMENT_PERIOD_OF_ALL_SUBJECTS_UP_TO_MONTH_12
- OP_RESEARCH_PRO00038502_GOG_3097_RAMP_301_KAMAT_ARM_1
- OP_RESEARCH_PRO00038502_GOG_3097_RAMP_301_KAMAT_ARM_2_LIPOSOMAL_DOXORUBICIN
- OP_RESEARCH_PRO00038502_GOG_3097_RAMP_301_KAMAT_ARM_2_PACLITAXEL
- OP_RESEARCH_PRO00038509_C2321014_ARM_A_EFSTATHIOU
- OP_RESEARCH_PRO00038509_C2321014_ARM_B_DOCETAXEL_EFSTATHIOU
- OP_RESEARCH_PRO00038509_C2321014_ARM_B_ENZALUTAMIDE_EFSTATHIOU
- OP_RESEARCH_PRO00038509_C2321014_SCREENING_EFSTATHIOU
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_A_KIM
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_B_KIM
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_C_KIM
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_D_KIM
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_E_KIM
- OP_RESEARCH_PRO00039131_NEO_ADJUVANT_ARM_F_KIM
- OP_RESEARCH_PRO00039131_V940_009_ADJUVANT_INELIGIBLE_FOR_RANDOMIZATION_KIM
- OP_RESEARCH_PRO00039131_V940_009_ADJUVANT_KIM
- OP_RESEARCH_PRO00039131_V940_009_NEO_ADJUVANT_SCREENING_KIM
- OP_RESEARCH_PRO00039131_V940_009_PRE_RANDOMIZATION_KIM
- OP_RESEARCH_PRO00039188_ZHANG_D516NC00001_PHASE_III_OPEN_LABEL_RANDOMIZED_STUDY_OF_OSIMERTINIB_ARM_2_VERSION_2.0
- OP_RESEARCH_PRO00039188_ZHANG_D516NC00001_PHASE_III_OPEN_LABEL_RANDOMIZED_STUDY_OF_OSIMERTINIB_WITH_DERUXTECAN_ARM_1_VERSION_2.0
- OP_RESEARCH_PRO00039188_ZHANG_D516NC00001_PHASE_III_OPEN_LABEL_RANDOMIZED_STUDY_OF_OSIMERTINIB_WITH_OR_WITHOUT_DERUXTECAN_SCREENING
- OP_RESEARCH_PRO00039425_PINGALI_MK2140_010_RANDOMIZED_PHASE_3_PLAN_A_ARM_1
- OP_RESEARCH_PRO00039425_PINGALI_MK2140_010_RANDOMIZED_PHASE_3_PLAN_B_ARM_2
- OP_RESEARCH_PRO00039425_PINGALI_MK2140_010_RANDOMIZED_PHASE_3_SCREENING_AND_RESCREENING_OPTIONAL
- OP_RESEARCH_PRO00039680_GOG_3115_ABBVIE_M25_231_KILOWSKI
- OP_RESEARCH_PRO00039815_HMCC_GI25_001_ARM_PLAN_A
- OP_RESEARCH_PRO00039815_HMCC_GI25_001_ARM_PLAN_B
- OP_RESEARCH_PRO00039815_HMCC_GI25_001_SCREENING_BASELINE
- OP_RESEARCH_PRO00039931_ABDELRAHIM_8951_CL_0305_PHASE_III_DOUBLE_BLIND_RANDOMIZED_STUDY_OF_ZOLBETUXIMAB_WITH_PEMBROLIZUMAB_AND_CAPEOX_ARM_B
- OP_RESEARCH_PRO00039931_ABDELRAHIM_8951_CL_0305_PHASE_III_DOUBLE_BLIND_RANDOMIZED_STUDY_OF_ZOLBETUXIMAB_WITH_PEMBROLIZUMAB_AND_CHEMO_CAPOX_OR_MFOLFOX6_SCREENING
- OP_RESEARCH_PRO00039931_ABDELRAHIM_8951_CL_0305_PHASE_III_DOUBLE_BLIND_RANDOMIZED_STUDY_OF_ZOLBETUXIMAB_WITH_PEMBROLIZUMAB_AND_MFOLFOX6_ARM_A
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_A_INDUCTION_WITH_CARBOPLATIN_AUC_5_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_A_INDUCTION_WITH_CISPLATIN_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_B_INDUCTION_WITH_NAB_PACLITAXEL_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_B_INDUCTION_WITH_PACLITAXEL_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_C_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_PLAN_D_ZHANG
- OP_RESEARCH_PRO00040000_EF_44_LUNAR_2_SCREENING_ZHANG
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_ANASTROZOLE_ARM_1_PLAN_B
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_AT_PROGRESSION_OF_DISEASE
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_EXEMESTANE_ARM_1_PLAN_C
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_LETROZOLE_SOC_ARM_1_PLAN_A
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_LOW_DOSE_TAMOXIFEN_ARM_2_PLAN_E
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_PRIOR_TO_REGISTRATION
- OP_RESEARCH_PRO00040327_NAIR_A012301_PHASE_III_TAMOXIFEN_ARM_1_PLAN_D
- OP_RESEARCH_PRO00040888_PURI_HMCC_BR25_001_INITIAL_SAFETY_LEAD_IN_FOLLOWED_BY_PHASE_II_TRIAL_TO_STUDY_ANTI_HCMV_THERAPY_IN_BREAST_CANCER_PATIENTS_ARM_1
- OP_RESEARCH_PRO00040888_PURI_HMCC_BR25_001_INITIAL_SAFETY_LEAD_IN_FOLLOWED_BY_PHASE_II_TRIAL_TO_STUDY_ANTI_HCMV_THERAPY_IN_BREAST_CANCER_PATIENTS_SCREENING
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_1A_HEPATOCELLULAR_CARCINOMA
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_1A_HEPATOCELLULAR_CARCINOMA_SCREENING
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_1B_HEPATOCELLULAR_CARCINOMA
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_2_HEPATOCELLULAR_CARCINOMA
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_3_BILIARY_TRACT_CANCER
- OP_RESEARCH_PRO00041696_ABDELRAHIM_RP2_003_COHORT_3_BILIARY_TRACT_CANCER_SCREENING
- OP_RESEARCH_PRO00042594_GOG_3119_INDUCTION_1_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_INDUCTION_2_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_MAINTENANCE_TREATMENT_ARM_A_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_MAINTENANCE_TREATMENT_ARM_B_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_OPTIONAL_EXTENDED_INDUCTION_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_PEMBROLIZUMAB_TREATMENT_FOR_PARTICIPANTS_WITHOUT_DISEASE_PROGRESSION_WHO_ARE_NOT_ELIGIBLE_FOR_MAINTENANCE_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_SUBSEQUENT_MAINTENANCE_TREATMENT_ARM_A_KAMAT
- OP_RESEARCH_PRO00042594_GOG_3119_SUBSEQUENT_MAINTENANCE_TREATMENT_ARM_B_KAMAT
- OP_RESEARCH_PRO0035580_BR22_SCREENING_BASELINE
- OP_RESEARCH_PRO0035580_BR22_TREATMENT
- OP_RITUXIMAB_WEEKLY_X_4
- OP_RITUXIMAB_375_EVERY_2_MONTHS_MAINTENANCE
- OP_RITUXIMAB_375_MG_M2_EVERY_21_DAYS
- OP_RITUXIMAB_500_MG_M2_EVERY_14_DAYS
- OP_ROMIDEPSIN
- OP_RSH_PRO00026304_INFORM_STUDY_ABDELRAHIM
- OP_RSH_PRO00036001_CA057_008_ARM_A_CC_92480_CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001_CA057_008_ARM_B_OPTION_1_CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001_CA057_008_ARM_B_OPTION_2_CARFILZOMIB_DEXAMETHASONE
- OP_RSH_PRO00036001_CA057_008_SCREENING
- OP_RSH_PRO00036343_IMCGP100_203_ARM_C
- OP_RSH_PRO00037490_ARM_A_TAR_200_DEVICE_IV_CETRELIMAB
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_1_Q_42_DAYS
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_1_Q21_DAYS
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_ARM_2_OBSERVATION
- OP_RSH_PRO00037694_ALLIANCE_A012103_JAIN_SCREENING
- OP_RSH_PRO00037695_HN009_ARM_1_AND_3
- OP_RSH_PRO00037695_HN009_ARM_2_AND_4
- OP_RSH_PRO00037695_HN009_BASELINE_SCREENING
- OP_RSH_PRO00037870_PERIOPERATIVE_COHORT_ADJUVANT_PERIOD
- OP_RSH_PRO00037870_PERIOPERATIVE_COHORT_NEOADJUVANT_PERIOD
- OP_RSH_PRO00038020_ZHANG_M23_721_SCREENING
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_1_WITH_CARBOPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_1_WITH_CISPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_2_WITH_CARBOPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_2_WITH_CISPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_3_WITH_CARBOPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_3_WITH_CISPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_4_WITH_CARBOPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_1_PHASE_2_COHORT_4_WITH_CISPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_2_PHASE_3_ARM_1_ARM_2_WITH_CISPLATIN
- OP_RSH_PRO00038020_ZHANG_M23_721_STAGE_2_PHASE_3_ARM_1_ARM_2_WITH_CARBOPLATIN
- OP_RSH_PRO00038031_ABDELRAHIM_PHASE_1_5FU_HT_FOLFIRI_HT_BEVACIZUMAB
- OP_RSH_PRO00038031_ABDELRAHIM_PHASE_1_5FU_HT_FOLFIRI_HT_CETUXIMAB
- OP_RSH_PRO00038031_ABDELRAHIM_PHASE_1_5FU_HT_FOLFOX_HT_BEVACIZUMAB
- OP_RSH_PRO00038031_ABDELRAHIM_PHASE_1_5FU_HT_FOLFOX_HT_CETUXIMAB
- OP_RSH_PRO00038031_ABDELRAHIM_PHASE_1_5FU_HT_SCREENING
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_TOPOTECAN
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_GEMCITABINE_EVERY_21_DAYS
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_IRINOTECAN_EVERY_42_DAYS
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_PEMETREXED_EVERY_21_DAYS
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_TISOTUMAB_VEDOTIN
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_ARM_2_VINORELBINE_EVERY_21_DAYS
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_PHASE_3_ARM_1_MK_2870
- OP_RSH_PRO00038214_RAMIREZ_MK_2870_020_GOG_3101_RUN_IN_SINGLE_ARM_MK_2870
- OP_RSH_PRO00038231_ZHANG_DS7300_188_IND144591_ARM_1_I_DXD
- OP_RSH_PRO00038231_ZHANG_DS7300_188_IND144591_ARM_2_SOC_LURBINECTEDIN
- OP_RSH_PRO00038231_ZHANG_DS7300_188_IND144591_ARM_2_SOC_TOPOTECAN
- OP_RSH_PRO00038231_ZHANG_DS7300_188_IND144591_SCREENING
- OP_RSH_PRO00038249_H_55540_AXATILIMAB
- OP_RSH_PRO00038325_ABLE_32_KAUSHIK_ARM_NADOFARAGENE_FIRADENOVEC
- OP_RSH_PRO00038342_ALE1001_SHAH_PHASE_1_and_PHASE_2_POST_ALLO_HSCT_MAINTENANCE_PHASE
- OP_RSH_PRO00038351_GOG_3096_PHASE_3_TOPOTECAN_4MG_M2_28_DAYS
- OP_RSH_PRO00038351_GOG_3096_PHASE_3_PLD_EVERY_28_DAYS
- OP_RSH_PRO00038351_GOG_3096_PHASE3_PACLITAXEL_EVERY_28_DAYS
- OP_RSH_PRO00038351_GOG_3096_PHASE_3_TOPOTECAN_1.25MG_M2_21_DAYS
- OP_RSH_PRO00038351_GOG_3096_PHASE_3_R_DXD_EVERY_21_DAYS
- OP_RSH_PRO00038360_PINGALI_JCAR017_FOL_001_EXTENDED_POST_TREATMENT_FOLLOW_UP_PERIOD
- OP_RSH_PRO00038360_PINGALI_JCAR017_FOL_001_LEUKAPHERESIS_AND_PRETREATMENT_PERIOD
- OP_RSH_PRO00038360_PINGALI_JCAR017_FOL_001_SCREENING
- OP_RSH_PRO00038360_PINGALI_JCAR017_FOL_001_TREATMENT_AND_POST_TREATMENT_PERIOD
- OP_RSH_PRO00038439_SHAH_AC220_168_BIOSAMPLE_SCREENING_ARM_OR_PERIOD_THAT_IS_“OPTIONAL
- OP_RSH_PRO00039535_MK5909_003_COHORT_A_1_ARM_2
- OP_RSH_PRO00039535_MK5909_003_COHORT_B_1
- OP_RSH_PRO00039797_SUN_MK_1022_ADJUVANT_ARM_B_NO_PCR_WITH_PEMBROLIZUMAB_AC
- OP_RSH_PRO00039797_SUN_MK_1022_ADJUVANT_ARM_B_NO_PCR_WITH_PEMBROLIZUMAB_OLAPARIB
- OP_RSH_PRO00039797_SUN_MK_1022_ADJUVANT_PHASE_ARM_A_IF_PCR_WITH_PEMBROLIZUMAB
- OP_RSH_PRO00039797_SUN_MK_1022_ADJUVANT_PHASE_ARM_B_NO_PCR_WITH_PEMBROLIZUMAB_CAPECITABINE
- OP_RSH_PRO00039797_SUN_MK_1022_NEOADJUVANT_PHASE_ARM_A
- OP_RSH_PRO00039797_SUN_MK_1022_NEOADJUVANT_TREATMENT_PHASE_ARM_B
- OP_RSH_PRO00039797_SUN_MK_1022_NEOADJUVANT_TREATMENT_PHASE_ARM_C
- OP_RSH_PRO00039797_SUN_MK_1022_SCREENING
- OP_RSH_PRO00039797_SUN_MK_1022_SURGERY_PHASE
- OP_RSH_PRO00039835_EFSTATHIOU_MK_2400_001_ARM_1
- OP_RSH_PRO00039835_EFSTATHIOU_MK_2400_001_ARM_2
- OP_RSH_PRO00039835_EFSTATHIOU_MK_2400_001_SCREENING
- OP_RSH_PRO00039923_ESNAOLA_PHASE_2_CMMP_WITH_PLANNED_NEOADJUVANT_THERAPY_PRIOR_TO_EMCS
- OP_RSH_PRO00040158_PRATH_A032201_ARM_1_PLAN_A
- OP_RSH_PRO00040158_PRATH_A032201_ARM_1_PLAN_B
- OP_RSH_PRO00040158_PRATH_A032201_ARM_2
- OP_RSH_PRO00040158_PRATH_A032201_SCREENING
- OP_RSH_PRO00041272_ZHANG_J3M_MC_JZQH_PLAN_1_ARM_A_OLOMORASIB_PLACEBO_PEMBRO
- OP_RSH_PRO00041272_ZHANG_J3M_MC_JZQH_PLAN_1_ARM_B_OLOMORASIB_PLACEBO_DURVA
- OP_RSH_PRO00041272_ZHANG_J3M_MC_JZQH_PLAN_2_ARM_A_ARM_B_OLOMORASIB_PLACEBO_MONOTHERAPY_MAINTENANCE
- OP_RSH_PRO00041272_ZHANG_J3M_MC_JZQH_PRESCREENING_AND_SCREENING
- OP_RSH_PRO00041362_EFSTATHIOU_78278343PCR3001_SCREENING
- OP_RSH_PRO00041362_EFSTATHIOU_78278343PCR3001_TREATMENT_ARM_1
- OP_RSH_PRO00041430_TRAN_NRG_GI011_DOSE_ESCALATED_RT_ARM_2_MFOLFIRINOX
- OP_RSH_PRO00041430_TRAN_NRG_GI011_DOSE_ESCALATED_RT_ARM_2_NAB_PACLITAXEL_GEMCITABINEABRAXANE
- OP_RSH_PRO00041430_TRAN_NRG_GI011_CHEMOTHERAPY_FOR_ARM_1_CHEMORADIATION_WITH_5_FU
- OP_RSH_PRO00041430_TRAN_NRG_GI011_CHEMOTHERAPY_FOR_ARM_1_CHEMORADIATION_WITH_CAPECITABINE
- OP_RSH_PRO00041430_TRAN_NRG_GI011_CHEMOTHERAPY_FOR_ARM_1_MFOLFIRINOX
- OP_RSH_PRO00041430_TRAN_NRG_GI011_CHEMOTHERAPY_FOR_ARM_1_NAB_PACLITAXEL_GEMCITABINE_ABRAXANE
- OP_RSH_PRO00041430_TRAN_NRG_GI011_CHEMOTHERAPY_FOR_ARM_1_NALIRIFOX
- OP_RSH_PRO00041430_TRAN_NRG_GI011_DOSE_ESCALATED_RT_ARM_2_NALIRIFOX
- OP_RSH_PRO00041680_ABDELRAHIM_HCC_23_116_PHASE_2_COHORT_A
- OP_RSH_PRO00041680_ABDELRAHIM_HCC_23_116_PHASE_2_COHORT_B
- OP_RSH_PRO00041680_ABDELRAHIM_HCC_23_116_SAFETY_LEAD_IN
- OP_RSH_PRO00041680_ABDELRAHIM_HCC_23_116_SCREENING
- OP_RSH_PRO00041696_ABDELRAHIM_RP2_COHORT_2_HEPATOCELLULAR_CARCINOMA_SCREENING
- OP_RSH_PRO00041722_NIRAVATH_RLY_2608_102_ARM_1
- OP_RSH_PRO00041722_NIRAVATH_RLY_2608_102_ARM_2
- OP_RSH_PRO00041722_NIRAVATH_RLY_2608_102_SCREENING
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_ARM_A_EVORPACEPT_TRASTUZUMAB_CAPECITABINE
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_ARM_B_EVORPACEPT_TRASTUZUMAB_ERIBULIN
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_ARM_C_EVORPACEPT_TRASTUZUMAB_GEMCITABINE
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_ARM_D_EVORPACEPT_TRASTUZUMAB_PACLITAXEL
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_ARM_E_EVORPACEPT_TRASTUZUMAB_VINORELBINE
- OP_RSH_PRO00041872_AT148009_MAI_SINGLE_ARM_PHASE_2_MULTICENTER_STUDY_OF_EVORPACEPT_IN_COMBINATION_WITH_TRASTUZUMAB_AND_CHEMOTHERAPY_SCREENING
- OP_RSH_PRO00042030_ZHANG_MK_6070_003_ARM_4_PART_B
- OP_RSH_PRO00042030_ZHANG_MK_6070_003_SCREENING_RESCREENING
- OP_RSH_PRO00042047_GUAN_C3651021_OPTIONAL_OPEN_LABEL_EXTENSION_ARM_B_PLAN_B_PONSEGROMAB_NAB_PACLITAXEL_AND_GEMCITABINE
- OP_RSH_PRO00042047_GUAN_C3651021_OPTIONAL_OPEN_LABEL_EXTENSION_ARM_B_PLAN_B_PONSEGROMAB_MFOLFIRINOX
- OP_RSH_PRO00042047_GUAN_C3651021_PHASE_2B_AND_3_ARM_A_PLAN_A_PONSEGROMAB_MFOLFIRINOX
- OP_RSH_PRO00042047_GUAN_C3651021_PHASE_2B_AND_3_ARM_A_PLAN_A_PONSEGROMAB_NAB_PACLITAXEL_AND_GEMCITABINE
- OP_RSH_PRO00042047_GUAN_C3651021_PRE_RANDOMIZATION_SCREENING_CHEMOTHERAPY_ONLY_NAB_PACLITAXEL_GEMCITABINE
- OP_RSH_PRO00042047_GUAN_C3651021_PRE_RANDOMIZATION_SCREENING_CHEMOTHERAPY_ONLY_MFOLFIRINOX
- OP_RSH_PRO00042503_GUAN_DS7300_202_ARM_EXPERIMENTAL_I_DXD
- OP_RSH_PRO00042503_GUAN_DS7300_202_ARM_INVESTIGATOR’S_CHOICE_DOCETAXEL
- OP_RSH_PRO00042503_GUAN_DS7300_202_ARM_INVESTIGATOR’S_CHOICE_IRINOTECAN_HCL
- OP_RSH_PRO00042503_GUAN_DS7300_202_ARM_INVESTIGATOR’S_CHOICE_PACLITAXEL
- OP_RSH_PRO00042503_GUAN_DS7300_202_SCREENING
- OP_RSH_PRO00042634_PINGALI_90014496LYM1001_SCREENING
- OP_RSH_PRO00042841_PRATH_CCTG_PR26_DOCETAXEL_STANDARD_ADT_ARPI_ARM_2
- OP_RSH_PRO00042841_PRATH_CCTG_PR26_STANDARD_ADT_ARPI_ARM_1
- OP_RSH_PRO00042841_PRATH_CCTG_PR26_SCREENING
- OP_RSH_PRO00043125_NIRAVATH_A012303_ARM_1_TRASTUZUMAB_PERTUZUMAB
- OP_RSH_PRO00043125_NIRAVATH_A012303_ARM_2_TRASTUZUMAB_AND_HYALURONIDASE
- OP_RSH_PRO00043125_NIRAVATH_A012303_ARM_3_WITH_PERTUZUMAB_TRASTUZUMAB_HY_ZZXF_PHESGO
- OP_RSH_PRO00043125_NIRAVATH_A012303_SCREENING
- OP_RSH_PRO00043760_3082_CL_0301_ABDELRAHIM_ASP3082_IN_COMBINATION_WITH_MFOLFIRINOX
- OP_RSH_PRO00043760_3082_CL_0301_ABDELRAHIM_ASP3082_IN_COMBINATION_WITH_NALIRIFOX
- OP_RSH_PRO00043760_3082_CL_0301_ABDELRAHIM_SCREENING
- OP_RSH_PRO00044071_EA8231_PRATH_ARM_A_PLAN_1_CARBOPLATIN_GEMCITABINE
- OP_RSH_PRO00044071_EA8231_PRATH_ARM_A_PLAN_2_CISPLATIN_GEMCITABINE
- OP_RSH_PRO00044071_EA8231_PRATH_ARM_A_PLAN_3_DOCETAXEL
- OP_RSH_PRO00044071_EA8231_PRATH_ARM_A_PLAN_4_PACLITAXEL
- OP_RSH_PRO00044071_EA8231_PRATH_ARM_B_SACITUZUMAB_SG_PEMBROLIZUMAB
- OP_RSH_PRO00044071_EA8231_PRATH_SCREENING
- OP_RSH_PRO00044268_NAIR_NRG_BR009_ARM_AC_THEN_WEEKLY_TAXOL
- OP_RSH_PRO00044268_NAIR_NRG_BR009_ARM_DOSE_DENSE_AC_FOLLOWED_BY_WEEKLY_PACLITAXEL
- OP_RSH_PRO00044268_NAIR_NRG_BR009_ARM_TC_X_4_CYCLES
- OP_RSH_PRO00044268_NAIR_NRG_BR009_SCREENING
- OP_RSH_PRO00045037_75276617AML3001_SHAH_SCREENING
- OP_SACITUZUMAB_GOVITECAN_D1D8_EVERY_21_DAYS
- OP_SALTZ
- OP_SIMPLIFIED_INFUSIONAL_FLUOROURACIL_LEUCOVORIN_EVERY_14_DAYS
- OP_SIPULEUCEL_T_EVERY_14_DAYS
- OP_SUBCUTANEOUS_PERTUZUMAB_TRASTUZUMAB_HYALURONIDASE_EVERY_21_DAYS
- OP_TAFASITAMAB_CXIX
- OP_TECLISTAMAB_CQYV_MAINTENANCE
- OP_TEMSIROLIMUS_WEEKLY
- OP_TISOTUMAB_VEDOTIN_EVERY_21_DAYS
- OP_TOPOTECAN_BEVACIZUMAB_EVERY_21_DAYS
- OP_TOPOTECAN_BEVACIZUMAB_EVERY_28_DAYS
- OP_TOPOTECAN_D1_D8_D15_EVERY_28_DAYS
- OP_TOPOTECAN_D1_D5_EVERY_21_DAYS
- OP_TORIPALIMAB
- OP_TRABECTEDIN_24_HR_AMBULATORY_PUMP_EVERY_21_DAYS
- OP_TRABECTEDIN_NO_AMBULATORY_PUMP_EVERY_21_DAYS
- OP_TRANSARTERIAL_CHEMOEMBOLIZATION
- OP_TRASTUZUMAB_EVERY_21_DAYS_PACLITAXEL_EVERY_7_DAYS
- OP_TRASTUZUMAB_LOADING_AND_MAINTENANCE_CAPECITABINE_EVERY_21_DAYS
- OP_TRASTUZUMAB_PACLITAXEL_EVERY_7_DAYS
- OP_TRASTUZUMAB_PERTUZUMAB_DOCETAXEL_EVERY_21_DAYS
- OP_TRASTUZUMAB_PERTUZUMAB_WEEKLY_PACLITAXEL_EVERY_21_DAYS
- OP_TRASTUZUMAB_PERTUZUMAB_LOADING_AND_MAINTENANCE_DOSE_EVERY_21_DAYS
- OP_TRASTUZUMAB_AND_HYALURONIDASE_EVERY_21_DAYS
- OP_TRASTUZUMAB_LOADING_AND_MAINTENANCE_DOSE_EVERY_21_DAYS
- OP_TREMELIMUMAB_ONCE_DURVALUMAB_EVERY_28_DAYS
- OP_TVEC
- OP_VDC
- OP_VINCRISTINE_EVERY_28_DAYS
- OP_VINORELBINE_D1D8_EVERY_21_DAYS
- OP_VIP
- OP_WEEKLY_CARBOPLATIN_AUC_1.5_WEEKLY_PACLITAXEL_PEMBROLIZUMAB_EVERY_21_DAYS
- OP_WEEKLY_ELOTUZUMAB_EVERY_28_DAYS
- OP_WEEKLY_NAB_PACLITAXEL_D1D8D15_EVERY_28_DAYS
- OP_XELOX_BEVACIZUMAB_EVERY_21_DAYS
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_BREXUCABTAGENE_AUTOLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_CILTACABTAGENE_AUTOLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_IDECABTAGENE_VICLEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_LISOCABTAGENE_MARALEUCEL
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_OBECABTAGENE_AUTOLEUCEL_HIGH_TUMOR_BURDEN_DOSAGE_REGIMEN
- OP_IP_CAGT_CYCLOPHOSPHAMIDE_FLUDARABINE_OBECABTAGENE_AUTOLEUCEL_LOW_TUMOR_BURDEN_DOSAGE_REGIMEN
- OP_IP_EP_EMA
- OP_IP_EPCORITAMAB_BYSP
- OP_IP_RESEARCH_CTL_H_43516_CARMEN
- OP_IP_RESEARCH_PRO00038339_YUEN_S2213_PHASE_III_RANDOMIZED_STUDY_OF_DARA_VCD_FOR_NEW_AL_AMYLOIDOSIS_CONSOLIDATION_ARM_2
- OP_IP_RESEARCH_PRO00038753_LIAO
- OP_IP_RESEARCH_PRO00040227_CYTB323I12201_KAZZAZ_PHASE_2_OPEN_LABEL_RAPCABTAGENE_AUTOLEUCEL_VERSION_COMPARATOR_FOR_GPA_OR_MPA
- OP_IP_RSH_PRO00039683_YUEN_PART_A_COHORT_1
- OP_IP_RSH_PRO00039683_YUEN_PART_A_COHORT_2
- OP_IP_RSH_PRO00039683_YUEN_PART_B
- OP_IP_RSH_PRO00040592_KAZZAZ_CYTB323J12201_RAPCABTAGENE_AUTOLEUCEL_ARM_1_PLAN_A
- OP_IP_RSH_PRO00042634_PINGALI_90014496LYM1001_ARM_1
- OP_IP_RSH_PRO00045037_75276617AML3001_SHAH_TREATMENT_PHASE
- OPDIVO_QVANTIG_NIVOLUMAB_HYALURONIDASE_NVHY_14_DAY_CYCLES_MONOTHERAPY
- OPDIVO_QVANTIG_NIVOLUMAB_HYALURONIDASE_NVHY_21_DAY_CYCLES_MONOTHERAPY
- OPDIVO_QVANTIG_NIVOLUMAB_HYALURONIDASE_NVHY_28_DAY_CYCLES_MONOTHERAPY
- PRO00039821_AC220_167_ARM_1
- PRO00039821_AC220_167_ARM_2
- PRO00039821_AC220_167_BASELINE_SCREENING
- PRO00039821_AC220_167_SUB_STUDY
- RESEARCH_HILL_CTL_H_43761_CRIMSON_NE
- RESEARCH_HILL_CTL_H_43761_CRIMSON_NE_FOLLOW_UP
- RESEARCH_HILL_CTL_H_43761_CRIMSON_NE_PROCUREMENT_ORDERS
- RESEARCH_CTL_GENERIC_BLOOD_COLLECTION_ORDERS
- RESEARCH_CTL_GENERIC_INFUSION_ORDERS
- RESEARCH_CTL_H_23574_CHARKALL_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_35626_LULLA_TACTAM
- RESEARCH_CTL_H_37966_RELY_30
- RESEARCH_CTL_H_37966_RELY_30_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_37966_RELY_30_INITIAL_PROCUREMENT_ORDERS
- RESEARCH_CTL_H_40466_MAGENTA
- RESEARCH_CTL_H_40466_MAGENTA_FOLLOW_UP_LABS_OP
- RESEARCH_CTL_H_44526_ANCHOR
- RESEARCH_CTL_H_46604_BESTA_DONOR_PROCUREMENT
- RESEARCH_FT522_H_53764_REGIMEN_B
- RESEARCH_H_45118_DONOR_PROCUREMENT_FOR_THIRD_PARTY_MULTIVIRUS_SPECIFIC_T_CELL_LINES
- RESEARCH_LULLA_GLYCAR_H_38942
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_PEGYLATED_LIPOSOMAL_DOXORUBICIN_40_VERSION_9_08_22_2016
- RESEARCH_PRO00012803_GOG0281_KAMAT_ARM_A_PEGYLATED_LIPOSOMAL_DOXORUBICIN_50_VERSION_9_08_22_2016
- RESEARCH_PRO00019188_RANDHAWA_CALB001A2301
- RESEARCH_PRO00020138_CHANG_ESR_17_13153
- RESEARCH_PRO00020925_ABDELRAHIM_ASTELLAS_PH3_GLOW
- RESEARCH_PRO00022968_KAMAT_NRG_GY018
- RSH_IP_OP_PRO00036433_SGN70_101_TREATMENT
- RSH_OP_PRO00036433_SGN70_101_SCREENING_BASELINE
- RSH_OP_PRO00036788_CAMBRIA_1_ARM_A
- RSH_OP_PRO00036788_CAMBRIA_1_ARM_B_CAMIZESTRANT
- RSH_OP_PRO00036788_CAMBRIA_1_SCREENING
- RSH_OP_PRO00037396_NRG_GY026_ARM_1
- RSH_OP_PRO00037396_NRG_GY026_ARM_2
- RSH_OP_PRO00037396_NRG_GY026_ARM_3
- RSH_OP_PRO00037917_BR23_001_ARM_1
- RSH_OP_PRO00037917_BR23_001_ARM_2
- RSH_OP_PRO00037917_BR23_001_SCREENING
- RSH_PRO00036343_IMCGP100_203_BASELINE_SCREENING
- Therapy_Plan_THERAPEUTIC_APHERESIS_PHOTOPHERESIS
- Therapy_Plan_HM_BARIATRIC_INFUSION
- Therapy_Plan_CAGT_ECULIZUMAB_SOLIRIS_FOR_AHUS
- Therapy_Plan_CAGT_BORTEZOMIB_VELCADE_INJECTION
- Therapy_Plan_CAGT_ZOLEDRONIC_ACID_ZOMETA_INFUSION
- Therapy_Plan_CAGT_IVIG_INFUSION
- Therapy_Plan_CAGT_ECULIZUMAB_SOLIRIS_FOR_PNH
- Therapy_Plan_CAGT_INTRAVENOUS_FLUID_IV
- Therapy_Plan_CAGT_ALLO_DAILY_ORDERS
- Therapy_Plan_CAGT_AUTO_DAILY_ORDERS
- Therapy_Plan_CAGT_CLINIC_PROCEDURE_W_CONSCIOUS_SEDATION
- Therapy_Plan_CAGT_COMMON_ORDERS
- Therapy_Plan_CAGT_DONOR_LEUKOCYTE_INFUSION_DLI
- Therapy_Plan_CAGT_FEMORAL_LINE_PLACEMENT_W_SCC_DONOR_CENTER
- Therapy_Plan_CAGT_DONOR_EVALUATION_NMDP_SIBLING
- Therapy_Plan_CAGT_POST_TRANSPLANT_IMMUNIZATIONS
- Therapy_Plan_CAGT_NEUPOGEN_STEM_CELL_MOBILIZATION_DEFAULT_PT_SUPPLIED
- Therapy_Plan_CAGT_STEM_CELL_MONITORING_DEFAULT_PT_SUPPLIED
- Therapy_Plan_CAGT_MOZOBIL_STEM_CELL_MOBILIZATION
- Therapy_Plan_CAGT_PRE_TRANSPLANT_WORKUP
- Therapy_Plan_IVIG_INFUSION_0.5_GM_KG_FOR_KIDNEY_TRANSPLANT_MAX_70_GRAMS
- Therapy_Plan_HEMODIALYSIS_THERAPY_PLAN
- Therapy_Plan_TRANSIENT_HEMODIALYSIS_THERAPY_PLAN
- Therapy_Plan_IVIG_BOOSTER_INFUSION
- Therapy_Plan_HEPATITIS_B_IMMUNE_GLOBULIN_HBIG_INFUSION
- Therapy_Plan_VALPROATE_SODIUM_DEPACON_INFUSION
- Therapy_Plan_IRON_DEXTRAN_COMPLEX_INFED_INFUSION
- Therapy_Plan_VEDOLIZUMAB_ENTYVIO_INFUSION
- Therapy_Plan_SOLIRIS_FOR_AHUS_ECULIZUMAB
- Therapy_Plan_PENTAMIDINE_NEBUPENT_INHALATION
- Therapy_Plan_FERRIC_GLUCONATE_FERRLECIT_INFUSION
- Therapy_Plan_CYCLOPHOSPHAMIDE_CYTOXAN_INFUSION
- Therapy_Plan_ARANESP_DARBEPOETIN
- Therapy_Plan_INTRAVENOUS_FLUID_IV_INFUSION
- Therapy_Plan_DENOSUMAB_BMWO_OSENVELT_INJECTION
- Therapy_Plan_ZOLEDRONIC_ACID_ZOMETA_INFUSION
- Therapy_Plan_BLANK_THERAPY_PLAN
- Therapy_Plan_CEREZYME_IMIGLUCERASE_INFUSION
- Therapy_Plan_BELATACEPT_NULOJIX_MAINTENANCE_INFUSION
- Therapy_Plan_VITAMIN_B12_CYANOCOBALAMIN_INJECTION
- Therapy_Plan_GOSERELIN_ZOLADEX_SQ_INJECTION
- Therapy_Plan_LEUPROLIDE_LUPRON_DEPOT_IM_INJECTION_MALE
- Therapy_Plan_SOLIRIS_FOR_PNH_ECULIZUMAB
- Therapy_Plan_ROMIPLOSTIM_NPLATE_SQ_INJECTION
- Therapy_Plan_FILGRASTIM_NEUPOGEN_SQ_INJECTION
- Therapy_Plan_FILGRASTIM_GRANIX_SQ_INJECTION
- Therapy_Plan_OCTREOTIDE_DEPOT_SANDOSTATIN_LAR_IM_INJECTION
- Therapy_Plan_LANREOTIDE_SOMATULINE_DEPOT_SQ_INJECTION
- Therapy_Plan_PEGFILGRASTIM_JMDB_FULPHILA_SQ_INJECTION
- Therapy_Plan_DEXAMETHASONE_DECADRON_INFUSION
- Therapy_Plan_CENTRAL_VENOUS_CATHETER_MAINTENANCE
- Therapy_Plan_DEFEROXAMINE_DESFERAL_INFUSION
- Therapy_Plan_BACLOFEN_LIORESAL_INTRATHECAL_INJECTION_TRIAL
- Therapy_Plan_THERAPEUTIC_PHLEBOTOMY
- Therapy_Plan_PENTAMIDINE_PENTAM_INFUSION
- Therapy_Plan_CRYOPRECIPITATE_TRANSFUSION
- Therapy_Plan_FRESH_FROZEN_PLASMA_TRANSFUSION
- Therapy_Plan_PLATELET_TRANSFUSION
- Therapy_Plan_BLOOD_TRANSFUSION
- Therapy_Plan_EPOETIN_ALFA_PROCRIT_INJECTION_NON_ONCOLOGY
- Therapy_Plan_INFLIXIMAB_MAINTENANCE_INFUSION
- Therapy_Plan_IVIG_BOOSTER_MULTI_DAY_INFUSION
- Therapy_Plan_METHOTREXATE_IM_INJECTION_ONCE
- Therapy_Plan_IVIG_INFUSION_1_GM_KG_FOR_KIDNEY_TRANSPLANT
- Therapy_Plan_SOLUMEDROL_INDUCTION_500_MG_METHYLPREDNISOLONE
- Therapy_Plan_CYCLOPHOSPHAMIDE_CYTOXAN_INFUSION_ONCE
- Therapy_Plan_CAGT_PALIFERMIN_KEPIVANCE_INJECTION
- Therapy_Plan_MICAFUNGIN_MYCAMINE_INFUSION
- Therapy_Plan_CIDOFOVIR_VISTIDE_INFUSION_FOR_KIDNEY_TRANSPLANT
- Therapy_Plan_SILTUXIMAB_SYLVANT_INFUSION
- Therapy_Plan_MORPHINE_INTRATHECAL_INJECTION_TRIAL
- Therapy_Plan_WINRHO_SDF_INJECTION
- Therapy_Plan_CYTOMEGALOVIRUS_IMMUNE_GLOBULIN_CYTOGAM_INFUSION
- Therapy_Plan_CIDOFOVIR_VISTIDE_INFUSION_FOR_CMV
- Therapy_Plan_POST_SPLENECTOMY_IMMUNIZATIONS
- Therapy_Plan_IVIG_BOOSTER_INFUSION_ST._JOHNS_DEFAULT_PT_SUPPLIED
- Therapy_Plan_COSYNTROPIN_CORTROSYN_INJECTION
- Therapy_Plan_GILENYA_FINGOLIMOD_FIRST_DOSE_PROTOCOL_DR._SIMPSON
- Therapy_Plan_THERAPEUTIC_APHERESIS_LDL_APHERESIS
- Therapy_Plan_THERAPEUTIC_APHERESIS_PLATELET_REDUCTION
- Therapy_Plan_THERAPEUTIC_APHERESIS_RBC_EXCHANGE
- Therapy_Plan_THERAPEUTIC_APHERESIS_THERAPEUTIC_PLASMA_EXCHANGE
- Therapy_Plan_THERAPEUTIC_APHERESIS_WBC_REDUCTION
- Therapy_Plan_STEM_CELL_DONOR_LYMPHOCYTE_COLLECTION
- Therapy_Plan_RHO_D_IMMUNE_GLOBULIN_RHOGAM_INJECTION
- Therapy_Plan_USTEKINUMAB_STELARA_INDUCTION_INFUSION
- Therapy_Plan_BASILIXIMAB_SIMULECT_INFUSION
- Therapy_Plan_LEUPROLIDE_ELIGARD_SQ_INJECTION
- Therapy_Plan_TOCILIZUMAB_TYENNE_INFUSION
- Therapy_Plan_IVIG_INDUCTION_INFUSION_0.4_GM_KG_DAILY_X5
- Therapy_Plan_IVIG_INDUCTION_INFUSION_0.6_GM_KG_DAILY_X4
- Therapy_Plan_BELIMUMAB_BENLYSTA_INFUSION
- Therapy_Plan_INFLIXIMAB_INFUSION
- Therapy_Plan_IVIG_INFUSION_1_GM_KG_FOR_LUNG_TRANSPLANT
- Therapy_Plan_IVIG_INFUSION_0.5_GM_KG_FOR_LUNG_TRANSPLANT
- Therapy_Plan_SOLUMEDROL_INDUCTION_1000_MG_METHYLPREDNISOLONE
- Therapy_Plan_SOLUMEDROL_INDUCTION_1250_MG_METHYLPREDNISOLONE
- Therapy_Plan_SOLUMEDROL_BOOSTER_WEEKLY_1000_MG_METHYLPREDNISOLONE
- Therapy_Plan_SOLUMEDROL_BOOSTER_MONTHLY_1000_MG_METHYLPREDNISOLONE
- Therapy_Plan_ABATACEPT_ORENCIA_INFUSION
- Therapy_Plan_GOLIMUMAB_SIMPONI_ARIA_INFUSION
- Therapy_Plan_ZOLEDRONIC_ACID_RECLAST_INFUSION
- Therapy_Plan_CERTOLIZUMAB_PEGOL_CIMZIA_INJECTION_400_MG
- Therapy_Plan_PEGLOTICASE_KRYSTEXXA_INFUSION
- Therapy_Plan_FERRIC_CARBOXYMALTOSE_INJECTAFER_750_MG_INFUSION
- Therapy_Plan_FERUMOXYTOL_FERAHEME_510_MG_INFUSION
- Therapy_Plan_PAMIDRONATE_AREDIA_INFUSION
- Therapy_Plan_DENOSUMAB_BMWO_STOBOCLO_INJECTION
- Therapy_Plan_EPOETIN_ALFA_PROCRIT_INJECTION_ONCOLOGY
- Therapy_Plan_BLOOD_and_PLATELET_TRANSFUSION
- Therapy_Plan_RESEARCH_SCREENING_PRO0009707_MTG_REIC_PC003_MILES
- Therapy_Plan_NEUROLOGY_ONLY_MIGRAINE_INFUSIONS
- Therapy_Plan_INTRAVENOUS_ANTIBIOTICS_THERAPY_PLAN
- Therapy_Plan_LEUPROLIDE_LUPRON_DEPOT_IM_INJECTION_FEMALE
- Therapy_Plan_ACUTE_HYPERSENSITIVITY_GUIDELINES
- Therapy_Plan_NATALIZUMAB_INFUSION_EVERY_4_WEEKS
- Therapy_Plan_OCRELIZUMAB_OCREVUS_INFUSION
- Therapy_Plan_NUSINERSEN_SPINRAZA_FOR_SPINAL_MUSCULAR_ATROPHY_SMA_LOADING_DOSE
- Therapy_Plan_NUSINERSEN_SPINRAZA_FOR_SPINAL_MUSCULAR_ATROPHY_SMA_MAINTENANCE_DOSE
- Therapy_Plan_USTEKINUMAB_STELARA_SUBCUTANEOUS_INJECTION_FOR_PSORIASIS
- Therapy_Plan_PATISIRAN_ONPATTRO_INFUSION
- Therapy_Plan_USTEKINUMAB_STELARA_SUBCUTANENOUS_INJECTION_FOR_CROHN_DISEASE_MAINTENANCE
- Therapy_Plan_STANDARD_4_HOUR_IOHEXOL_OMNIPAQUE_CLEARANCE_FOR_MEASURING_GFR
- Therapy_Plan_RITUXIMAB_RITUXAN_SMITH_1101_RHEUMATOLOGY
- Therapy_Plan_ULTOMIRIS_FOR_PNH_RAVULIZUMAB_CWVZ
- Therapy_Plan_CRIZANLIZUMAB_ADAKVEO_INFUSION
- Therapy_Plan_INFLIXIMAB_DYYB_INFLECTRA_INFUSION
- Therapy_Plan_LUSPATERCEPT_REBLOZYL_INJECTION_EVERY_3_WEEKS
- Therapy_Plan_ORITAVANCIN_ORBACTIV_INFUSION
- Therapy_Plan_TEPROTUMUMAB_INFUSION
- Therapy_Plan_RITUXAN_PVVR_RUXIENCE_SMITH_1101
- Therapy_Plan_EPTINEZUMAB_VYEPTI_INFUSION
- Therapy_Plan_OBINUTUZUMAB_1000_MG_MAINTENANCE_INFUSION_EVERY_6_MONTHS
- Therapy_Plan_OUTPATIENT_ELECTROLYTE_REPLACEMENT
- Therapy_Plan_DESMOPRESSIN_0.3_MCG_KG_INFUSION_FOR_STIMULATION_TEST_MAX_DOSE_20_MCG
- Therapy_Plan_RETACRIT_EPOETIN_ALFA_EPBX
- Therapy_Plan_ANIFROLUMAB_SAPHNELO_INFUSION
- Therapy_Plan_AVALGLUCOSIDASE_ALFA_NGPT_INFUSION
- Therapy_Plan_INFLIXIMAB_AXXQ_AVSOLA_INFUSION
- Therapy_Plan_INFLIXIMAB_AXXQ_AVSOLA_MAINTENANCE_INFUSION
- Therapy_Plan_ORITAVANCIN_KIMYRSA_INFUSION
- Therapy_Plan_RITUXIMAB_ABBS_TRUXIMA_SM_1101
- Therapy_Plan_EFGARTIGIMOD_ALFA_INFUSION_VYVGART_OR_EFGARTIGIMOD_ALFA_AND_HYALURONIDASE_QVFC_SQ_INJECTION_VYVGART_HYTRULO
- Therapy_Plan_VEDOLIZUMAB_ENTYVIO_INFUSION_LOADING_DOSE_ONLY
- Therapy_Plan_BEVACIZUMAB_INFUSION_EVERY_21_DAYS
- Therapy_Plan_DEGARELIX_SUBCUTANEOUS_INJECTION_LOADING_DOSE_ONLY
- Therapy_Plan_DEGARELIX_SUBCUTANEOUS_INJECTION_LOADING_and_MAINTENANCE
- Therapy_Plan_RISANKIZUMAB_RZAA_SKYRIZI_INFUSION
- Therapy_Plan_GROWTH_HORMONE_SUPPRESION_TEST
- Therapy_Plan_INCLISIRAN_LEQVIO_SUBCUTANEOUS_INJECTION
- Therapy_Plan_GLUCAGON_STIMULATION_TEST
- Therapy_Plan_DESMOPRESSIN_STIMULATION_TEST
- Therapy_Plan_VUTRISIRAN_AMVUTTRA_SUBCUTANEOUS_INJECTION
- Therapy_Plan_LONG_10_HOUR_IOHEXOL_OMNIPAQUE_CLEARANCE_FOR_MEASURING_GFR
- Therapy_Plan_ROZANOLIXIZUMAB_RYSTIGGO_INFUSION
- Therapy_Plan_RESEARCH_PRO00037880_INFUSION_TREATMENT_HUANG
- Therapy_Plan_TOCILIZUMAB_AAZG_TYENNE_INFUSION_FOR_RHEUMATOLOGY
- Therapy_Plan_ARANESP_DARBEPOETIN_FOR_CKD
- Therapy_Plan_DONANEMAB_KISUNLA_TITRATED_DOSING_INFUSION
- Therapy_Plan_OBINUTUZUMAB_1000_MG_INFUSION_AT_WEEK_0_2_24_AND_26
- Therapy_Plan_IVIG_INFUSION_0.4_GM_KG_EVERY_4_WEEKS
- Therapy_Plan_BENRALIZUMAB_FASENRA_SQ_EVERY_4_WEEKS
- Therapy_Plan_BENRALIZUMAB_FASENRA_SQ_EVERY_8_WEEKS_MAINTENANCE
- Therapy_Plan_ROMOSOZUMAB_EVENITY_SQ_EVERY_4_WEEKS
- Therapy_Plan_RESEARCH_PRO00024239_GABER_ISATUXIMAB_INFUSION
- Therapy_Plan_CARFILZOMIB_KYPROLIS_FOR_AMR
- Therapy_Plan_ETESEVIMAB_BAMLANIVIMAB_INFUSION
- Therapy_Plan_RITUXIMAB_1000_MG_FOR_RHEUMATOLOGY
- Therapy_Plan_RITUXIMAB_ABBS_TRUXIMA_375_MG_M2
- Therapy_Plan_RITUXIMAB_ABBS_TRUXIMA_375_MG_M2_NEUROLOGY_RHEUMATOLOGY
- Therapy_Plan_RITUXIMAB_ABBS_TRUXIMA_500_MG
- Therapy_Plan_RITUXIMAB_ABBS_TRUXIMA_ONCE
- Therapy_Plan_THYMOGLOBULIN_FOR_KIDNEY_TRANSPLANT_REJECTION
- Therapy_Plan_FERUMOXYTOL_FERAHEME_1020_MG_INFUSION
- Therapy_Plan_FERRIC_CARBOXYMALTOSE_INJECTAFER_15_MG_KG_INFUSION
- Therapy_Plan_BEZLOTOXUMAB_ZINPLAVA_INFUSION
- Therapy_Plan_FERRIC_DERISOMALTOSE_MONOFERRIC_INFUSION
- Therapy_Plan_FULVESTRANT
- Therapy_Plan_ADAMTS13_ADZYNMA_WEEKLY_INFUSION
- Therapy_Plan_SECUKINUMAB_COSENTYX_INFUSION
- Therapy_Plan_SALINE_SUPPRESSION_TEST_FOR_HYPERALDOSTERONISM
- Therapy_Plan_RISANKIZUMAB_RZAA_SKYRIZI_LOADING_DOSE_INFUSION_FOR_ULCERATIVE_COLITIS
- Therapy_Plan_AXATILIMAB_NIKTIMVOTM_INFUSION
- Therapy_Plan_ZOLEDRONIC_ACID_ZOMETA_INFUSION_EVERY_6_MONTHS
- Therapy_Plan_HEMATOLOGY_LAB_THERAPY_PLAN
- Therapy_Plan_LEQEMBI_10_MG_KG_INFUSION
- Therapy_Plan_UPLIZNA_THERAPY_PLAN
- Therapy_Plan_CAGT_POST_ALLOGENEIC_STEM_CELL_TRANSPLANT_IMMUNIZATIONS
- Therapy_Plan_CYTOMEGALOVIRUS_IMMUNE_GLOBULIN_100_150_MG_KG_FOR_PANCREAS_TRANSPLANT
- Therapy_Plan_VYVGART_HYTRULO_WEEKLY_SQ_FOR_CIDP
- Therapy_Plan_JUBBONTI_THERAPY_PLAN
- Therapy_Plan_BMT_CERT_EMERGENCY_ORDERS
- Therapy_Plan_LEUPROLIDE_DEPOT_LUPRON_Q12WEEKS
- Therapy_Plan_LASIX_BUMEX_THERAPY_PLAN
- Therapy_Plan_CAGT_POST_AUTOLOGOUS_STEM_CELL_TRANSPLANT_IMMUNIZATIONS
- Therapy_Plan_TOCILIZUMAB_CABMR_INFUSION
- Therapy_Plan_PROLIA_DENOSUMAB_FOR_CLINIC_INFUSION_CENTERS_USE_ONLY
- Therapy_Plan_TOFERSEN_QALSODY_INTRATHECAL_INJECTION
- Therapy_Plan_PEMIVIBART_PEMGARDA
- Therapy_Plan_DONANEMAB_KISUNLA_STANDARD_DOSING_INFUSION
Updated 5-7-2026